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ABSTRACT 
REGULATION OF NUCLEAR RESPIRATORY FACTOR-1 EXPRESSION BY 17P-
ESTRADIOL: A NEW MECHANISM FOR COORDINATING MITOCHONDRIAL 
GENE EXPRESSION 
Kathleen A. Mattingly 
March 22, 2007 
The mechanisms by which estrogens regulate mitochondrial activity are not 
completely understood. Chronic treatment of ovariectomized rats with estradiol (E2) 
increased the amount of Nuclear Respiratory F actor-1 (NRF -1) protein in cerebral blood 
vessels. NRF-1 is a transcription factor that regulates the expression of nuclear-encoded 
mitochondrial genes including mitochondrial transcription factor A (TF AM), which, in 
tum, controls transcription of the mitochondrial genome. Here, I tested the hypothesis 
that E2 increases NRF -1 transcription through a genomic activation of estrogen receptor 
(ER) resulting in a coordinate increase in nuclear- and mitochondrial- encoded genes, 
mitochondrial respiratory activity, and mitochondrial biogenesis. E2 increased NRF-1 
mRNA and protein in MCF-7 breast and H1793 lung adenocarcinoma cells in a time-, 
concentration-, and ER-dependent manner. E2-induced NRF-1 expression was inhibited 
by Actinomycin D, but not by inhibitors of the PI3K or MAPK pathways, indicating a 
genomic mechanism of E2 action. An estrogen response element in the NRF -1 promoter 
bound ERa and ERP in vitro and in chromatin immunoprecipitation assays in MCF-7 
cells and activated reporter gene expression in transfected cells. The E2-induced increase 
in NRF-1 was followed in time by increased TFAM; Tfam-regulated, mtDNA-encoded 
lV 
CO! and ND!; and mitochondrial biogenesis. The selective ER modulators (SERMs) 4-
hydroxytramoxifen (4-0HT) and raloxifene (RAL) also increased NRF-1 expression by a 
mechanism involving ER nongenomic and genomic activities. E2, 4-0HT, and RAL also 
increased NRF-1 expression in Human Umbilical Vein Endothelial Cells (HUVEC) by a 
genomic ER mechanism. Exposure to Diesel Exhaust Particle Extracts (DEPE) may 
promote vascular disease and DEPE are antagonists of genomic estrogen responses. 
DEPE suppressed the basal expression ofNRF-1 in HUVEC and ablated the stimulatory 
effect ofE2, 4-0HT, and RAL on NRF-1 transcription. Lastly, a known cardioprotective 
phytoestrogen, resveratrol, stimulated NRF -1 expression in HUVEC and inhibited the 
ability ofDEPE to suppress basal NRF-l. In summary, the research presented here 
characterizes a possibly important ER-mediated pathway to account for the observed 
beneficial effects of E2 on mitochondrial function. These results suggest that 
administration of E2 or SERMs may be beneficial in treating pathological conditions 
involving mitochondrial dysfunction including heart disease, neurodegenerative 
disorders, and cancer. 
v 
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Estrogen Receptor Structure, Classical Function, and Tissue Distribution 
Estrogen action in the cell is mediated by binding to estrogen receptors (ER) in 
the cell nucleus. ER, like other steroid receptors, is a member of the class I 
steroid/nuclear receptor superfamily of transcriptional enhancers. There are two subtypes 
ofER, ER alpha (ERa) and ER beta (ER~). The ER protein is divided into six domains 
termed A-F (Figure 1) (1). AlB is the variable N-terminal domain, which regulates 
transcription through its activating factor 1 (AF-l) in a ligand-independent and cell-
specific manner. This region contains low amino acid (aa) homology between ERa and 
ER~. In contrast, the DNA binding domain (DBD), located in domain C, has the highest 
aa homology when the two ER subtypes are compared. The ligand binding domain 
(LBD) and activation function-2 (AF-2) in the C-terminal E and F domains share 59% 
and 18% aa homology, respectively (1,2). AF-2 interacts with corepressors and 
coactivators in a ligand-dependent manner. The high degree of homology in the LBD 
allows ERa and ER~ to form heterodimers which can bind to estrogen response elements 




hERf3 '-----'==--- 59 
144 227 255 504 530 
Figure 1: Illustration of the domains and percent homology between human ERa 
and ER~. The percent aa homology between the A-F domains is indicated in the ER~ 
diagram. The aa position of the end of each domain is also indicated (2,4). 
2 
of ERa/ERa or ERP/ERP and heterodimers of ERa/ERp and bind with high affinity to 
EREs in the promoters of target genes. In addition to EREs, ERa and ERP can interact 
directly with other DNA-bound transcription factors, e.g. Spl or API sites and up-
regulate transcription through a tethering mechanism (5,6). 
ERa and ERP are not distributed uniformly in the tissues of the body. While 
some tissues express exclusively ERa or ERP, other tissues express both ER sUbtypes 
(1). In the rat, ERa was detected by RT-PCR in ovary, uterus, testis, prostate, 
epididymis, bladder, pituitary, liver, kidney, adrenal, and heart (7). ERP was found in rat 
ovary, uterus, testis, prostate, epididymis, bladder, pituitary, lung, several regions of the 
brain, and in the spinal cord (7). ERa and ERP are expressed in both normal human 
breast and in breast cancers (8-11). In fact, ratios of the ER subtype have been shown to 
be altered during carcinogenesis. Expression of both ERa and ERP in breast cancer 
indicates a poor prognosis (12). It has been suggested that over-expression ofERP when 
occupied by an antiestrogen, activates the AP-l transcription factor at AP-l response 
element sites leading to gene expression that promotes cell proliferation (12). 
On the other hand, Jan-Ake Gustafsson has proposed that ERa has a proliferative role in 
the cell, while ERP may have an anti-proliferative role (13). Recently it has been 
recognized that ERP is the major subtype present in the normal mammary gland and in 
benign breast cancer (14). Hence, loss ofERP may cause breast cancer cell proliferation 
(15). ERP has at least 6 isoforms due to 2 different transcription start sites and 
alternative splicing (16). The role of these splice variants is of great interest in breast 
carcinogenesis because these variants can form heterodimers with ERa. Sequestering of 
3 
ERa by ERP isoforms, may lead to over-expression of growth factor receptors in the cell, 
allowing the normally non-proliferative cells to proliferate (17). ERpcx is an example of 
a splice variant ofERP capable of sequestering ERa (18). hERP 1 (530 aa long form) is 
identical to ERBcx in exons 1-7. However, exon 8 is completely different containing 26 
unique aa residues in place of the 61 aa residues that normally encode part of helix 11 
and helix 12. This mutation abolishes the AF-2 domain and amino acids responsible for 
ligand binding. While ERpcx does not bind to consensus EREs, it does preferentially 
bind to ERa rather than ERP, resulting in a dominant negative effect on ERa gene 
transacti vati on (18). 
Breast Cancer, Lung Cancer, and Estrogen 
Breast cancer is the most frequently diagnosed cancer in women in the western 
world (19). Of the total cancer burden worldwide, breast cancer comprises 115 of the 
total (20). This figure includes a 33% increase in breast cancer incidence in the 1990s, 
which comprised a total of 1,050,346 new cases in 2000 (20). The progression of genetic 
events that results in formation of a breast tumor are still not clear. However, it well 
established that exposure to estrogens over a lifetime places women at a higher risk for 
developing breast cancer than men (21-24). Estrogens are hormonal regulators of cell 
growth and differentiation. They also regulate the physiological functions of many 
peripheral tissues in the male and female reproductive system. Tissues regulated by 
estrogens include ovaries, vagina, mammary gland, and uterus in females and testis, 
prostate, and epididymis in males (25). The primary circulating form of estrogen in 
premenopausal women, i.e., 17p-Estradiol (E2) is needed for the growth and development 
4 
of the mammary gland and it has been implicated in the promotion of breast cancer (26). 
In fact, many human breast cancers are hormone-dependent in early stages and later 
progress to a hormone independent stage if not treated. In these early stages, tumors are 
responsive to antiestrogens, some of which are also referred to as Selective Estrogen 
Receptor Modulators (SERMs) because they have mixed estrogen agonist/antagonist 
activity, such as tamoxifen (TAM). ERa is over-expressed in breast tumors and is used 
as a prognostic indicator of TAM therapy (27). About two-thirds of patients with ERa-
positive tumors will react favorably to treatment with TAM, as indicated by enhanced 
patient survival (17). 
Results from case-control studies, which examine the relationship between 
diseases and risk factors after disease occurrence, indicated that women may be more 
susceptible to the carcinogenic potential of smoking on the lungs (28). However, cohort 
studies, which identify a patient group that is tracked over time for future development of 
disease after exposure to a causative agent, have resulted in conflicting data (28). Despite 
these contradictory results, much like breast cancer, estrogens are considered a risk factor 
for lung cancer in females (29). Overall, the risk of lung cancer in females has been 
suggested to be 2-fold higher in comparison to male smokers (30) Tumor xenografts and 
lung cancer cells in culture have been shown to proliferate in response to E2 (29,31). 
Additionally, lung epithelial cells and lung cancer cells express both ERa and ER~ 
(reviewed in (32)). In fact, treatment of transgenic mice expressing an ERE regulated 
luciferase gene with E2 resulted in a ~ 15 fold increase in relative luciferase activity in the 
lung (33). 
5 
Lung carcinomas are divided into small cell lung carcinoma (SCLC) and non-
small cell lung carcinoma (NSCLC) with NSCLC comprising the majority of lung 
cancers including adenocarcinomas, squamous cell carcinomas, large cell carcinomas, 
and adeno-squamous cell carcinomas. Female smokers have a 2.5-fold increased risk of 
developing lung adenocarcinoma compared to male smokers (34). In fact, 
adenocarcinomas comprise approximately three-fourths of primary lung tumors in 
females and only one third in males (35-37). 
Although the presence of both ER subtypes has been detected in lung cells, ERa 
has been determined not to playa significant role in the progression lung cancers (38,39). 
However, ERP is predominantly expressed in normal lung and lung tumors and thought 
to mediate the actions ofE2 (7,29). Studies in ERP knockout mice (PERKO) support a 
role for ERP in the normal lung. PERKO mice display abnormal alveolar development 
(40). In lung tumors, ERP has been shown to be an essential contributor to the 
development ofNSCLC (38,39). Use of the classical ER antagonist ICI 182,780 on ERP 
expressing lung tumors reduced the proliferation ofNSCLC and this effect is proposed to 
be mediated through ERP (38). Recently, the analysis of ERa and ERP expression and 
activity in human lung adenocarcinoma cell lines and normal lung fibroblasts revealed 
that E2 stimulated proliferation in lung cancer cells derived only from female patients 
(32). Lung adenocarcinoma cell lines derived from females were inhibited by 4-
hydroxytamoxifen (4-0HT) and ICI 182,780 treatment, in agreement with previous 
studies. In contrast, lung adenocarcinoma cell lines derived from male patients, although 
expressing equal amounts of ERa and ERP as those from females, were unresponsive to 
the effects ofE2, 4-0HT and ICI 182,780 (32). 
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In general, the mechanisms by which estrogens may promote both breast and lung 
tumors are not yet fully understood. However, the presence ofER in both tumor types 
and the strong association of a proliferative response to E2 makes breast and lung cancers 
potential targets of therapies designed to prevent the tumorogenic effects of estrogens. 
ERE and Coactivator Interactions with ER 
The effects of estrogens in the cell depends on the genes regulated by ER; this in 
tum depends on the affinity ofER interaction with the target gene promoter (41,42). The 
nucleotide sequence of the ERE impacts ERa and ER~ conformation which leads to a 
change in the coactivator binding pocket affecting the recruitment of coactivators to the 
ER-ERE (43). Deviation from the perfect consensus ERE correlates with decreasing 
affinity ofER-ERE binding (42). 
Coactivators interact with DNA bound liganded-ER leading to recruitment of 
chromatin remodeling complexes, "loosening" of nucleosomal structure, recruitment of 
general transcription factors, and increased transcription of target genes (44). The 
SRC/p 160 family of coactivators, which interacts directly with the ER, is composed of 
three members: SRC-1, SRC-2/TIF-2/GRIP1, and SRC-3/ACTRlAIB1 (44). These 
SRC/p 160 family members contain several conserved domains including a central 
domain with three LXXLL motifs. The LXXLL motif forms an amphipathic a-helix that 
interacts with the LBD and the N-terminus ofligand-bound ER (45). Additionally, the C-
termini ofSRC-1 and SRC-3 contain histone acetyltransferase (HAT) activity (46,47). 
The HAT activity in the C-terminus results in acetylation of lysine groups on the 
histone/nucleosomal complex leading to an opening of the chromatin. p 160 coacti vators 
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also interact with the AF-l domain of ERa (48). Once bound to the ER-ERE complex, 
the SRC/p160 coactivators can recruit subsequent proteins involved in opening of the 
chromatin through two separate transcription activation domains, AD-l and AD-2 (49). 
AD-l mediates the recruitment ofCBP/p300 coactivators and acetyltransferases while the 
AD-2 domain recruits Coactivator-associated Arginine Methyltransferase (CARMI) (49) 
and Protein Arginine Methyltransferase 1 (PRMT1), secondary protein-modifying 
enzymes (50). Overall, this recruitment leads to opening ofthe chromatin by remodeling 
complexes, such as the SWIISNF complex and upregulation of transcription (51). 
Selective Estrogen Receptor Modulators 
SERMs act as mixed estrogen agonist/antagonists when bound to the LBD of 
ERs. They mediate their effects on ER function through direct binding to ER in the LBD 
(52). The differential effects in SERM activity, i.e., agonist in some tissues such as bone 
and uterus and antagonist in breast are attributed to the recruitment of corepressors 
instead of coactivators to the ERs and tissue specific expression of coregulators which 
bind to the SERM-ER complex to mediate downstream effects (52). Examples of 
SERMs include 4-0HT, the active metabolite oftamoxifen (53) and raloxifene (RAL). 
4-0HT is an antagonist in breast and an agonist in uterine tissue (54). Thus, while 
efficacious in treating ERa positive breast cancer, 4-0HT increases the risk of 
endometrial cancer (54). The differential effect of 4-0HT in endometrial tissue has been 
attributed to a high level ofSRC-l expression in the endometrium allowing the 4-0HT-
ER complex to recruit SRC-l and coactivate genes whereas tissues with low SRC-l 
result in corepressor recruitment to the 4-0HT-ER complex and no transcription (55). 
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RAL differs from 4-0HT in that it can act as an estrogen agonist in bone and liver, but it 
functions as an antagonist in uterus and breast (56). Ideally, a perfect SERM could not 
only provide a way to target ER positive breast tumors, but would serve as an alternative 
to hormone replacement therapy (HRT) that might protect women against 
postmenopausal breast or endometrial cancer (57). To add a layer of complexity to the 
ER-SERM story, ERa and ERP both have unique biological responses to estrogens 
(including phytoestrogens and endocrine disruptors) and SERMs (2). It has been 
suggested that the asymmetrical ratios of ER heterodimers and homodimers expressed in 
tissues containing both subtypes may be an indicator of a subtle and yet undescribed way 
to regulate cell-type-specific and tissue-type-specific response to estrogens and SERMs 
(58). 
In recent years, Diesel Exhaust Particles (DEP) have received attention for their 
potential role as endocrine disrupting agents. DEP are mostly fine particles ranging in 
size from 0.2-0.5 !lm and are composed of a variety of organic compounds and heavy 
metals (59). Both antiestrogenic and estrogenic effects ofDEPs have been shown in 
MCF -7 cells (60,61). Antiandrogenic effects have also been reported in a prostate cancer 
cell line, PC3/AR (62). The effects ofDEPs are thought to be mediated in part by 
polycyclic aromatic hydrocarbons (P AHs) which are a major component of DEPs and are 
agonist for the AhR receptor (59,60,62). It is known that AhR agonists can direct both 
antiestrogenic (63,64) and also antiandrogenic effects (60,62) through signaling between 
ER and AhR 
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Mitochondrial Function and Maintenance 
Eukaryotic mitochondria contain several metabolic pathways that are required for 
homeostasis and energy production. These include A TP synthesis via oxidative 
phosphorylation, heme biosynthesis, p-oxidation, metabolism of certain amino acids, 
cholesterol synthesis, and formation and exportation of iron-sulfur clusters (65). 
Mitochondria also mediate apoptosis by integrating cell death signals (65). 
Mitochondrial DNA (mtDNA) is a 16.5 kb circular genome encoding 13 mRNAs, 2 
rRNAs, and 22 tRNAs (65,66). The mRNAs encode protein subunits of respiratory 
complex I (7 subunits), III (1 subunit), IV (3 subunits), and V (2 subunits) which are 
required for proper function of each complex (66). The remaining subunits of the 
respiratory complex as well as other proteins involved in mtDNA metabolism (~1 00 
proteins) and mitochondrial function are nuclear encoded (67,68). Once translated in the 
cytoplasm, these proteins are targeted to the mitochondria through a signal sequence and 
imported into the mitochondria via translocases (69). 
Mitochondrial transcription is initiated at two promoters (PL and PH) located in the 
D-Ioop regulatory region (65). Transcription is initiated at these sites through the binding 
of mitochondrial RNA (mtRNA) polymerase and the mitochondrial transcription factors 
mitochondrial transcription factor A (Tfam) and mitochondrial transcription factor Bl 
(TFB 1) and mitochondrial transcription factor B2 (TFB2), hereafter referred to as TFBs 
(65,70). Both Tfam and TFBs are nuclear-encoded mitochondrial proteins whose 
transcription is regulated by the transcription factor nuclear respiratory factor 1 (NRF -1) 
(67). 
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Estrogen Activity in Mitochondria 
Several studies have revealed that estrogens may exert direct or indirect effects on 
mitochondrial function in a variety of tissues with particular attention to their 
neuroprotective affects (71,72). It is known that E2 can protect against ATP depletion 
within the cell, reactive oxygen species (ROS) generation caused by exposure to 3-
nitroproprionic acid, and mitochondrial membrane potential decline (73). Recently, ER~ 
was localized to the mitochondria in several cell types of the brain including primary 
cerebral cortical and hippocampal neurons, primary cardiomyocytes, and murine 
hippocampal cells (74). The mitochondrial localization was independent of the 
differentiation state of the cells. The localization ofER~ was demonstrated by a variety 
of complementary techniques including immunocytochemistry, immunoblotting, and 
mass spectrometry (74). The mitochondrial localization of ERa and ER~ has also been 
detected in MCF-7 human breast cancer cells where treatment with E2 enhanced ER 
mitochondrial localization in a concentration- and time-dependent manner (75). An 
increase in transcript levels of the mtDNA-encoded genes cytochrome c oxidase subunits 
I and II was also detected with E2 treatment. This increase was inhibited by the ER 
specific antagonist ICI 182,780 demonstrating that these observations were ER dependent 
(75). 
Mitochondrial proteins are targeted to the mitochondria through mitochondrial 
targeting protein sequences (mTPS), and they are post-translationally imported into the 
mitochondria. To determine if ERa and ER~ contain mitochondrial targeting sequences, 
Chen et al. analyzed the primary aa sequence of human ERa and human ER~ using the 
TargetP program (75). The authors reported that aa sequence 220-270 ofER~ contains a 
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number of positively charged regions characteristic ofmTPS (score of 0.73 out of 1.0). 
The secondary structure program "Predator" indicated that the aa sequences 221-230 and 
251-260 have a tendency to form a-helical structures characteristic of mTPS. An 
internal sequence (aa 231-280) of human ERa also contained a concentration of 
positively charged residues consistent with a mitochondrial targeting protein sequence 
(mTPS). However, the TargetP program predicted that this region had lower probability 
to be an mTPS, i.e., score of 0.45 (75). The presence of a targeting sequence was 
suggested to explain how a normally nuclear protein, i.e., ER, could also be located in 
mitochondria (75). 
A second paper by Chen et al. further examined the localization ofER to 
mitochondria by determining that both nuclear and mitochondrial proteins extracted from 
MCF-7 cells bound to several different mitochondrial EREs (mtEREs) detected in the D-
loop regulatory region and to selected nuclear EREs (76). Competition binding 
experiments demonstrated that the binding was sequence-specific and enhanced by E2 in 
a time- and concentration-dependent manner. Through antibody binding in supershift 
assays, the authors concluded that ERB. was the predominant protein binding to mtEREs 
in MCF-7 cell extracts (76). However, this recent body ofliterature regarding 
mitochondrial-localized ER has generated controversy. One group reported that ER~ was 
not detectable in mouse liver mitochondria as analyzed by MALDI-TOF mass 
spectrometry (77). On the other hand, the mitochondrial localization ofER may be cell-
specific because ER~ was recently identified in human heart mitochondrial protein 
extracts by MALDI-TOF (78). 
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Lessons from Knockout and Ovariectomized Mice 
The role of estrogens in mitochondrial function is well-established from studies 
with male ERa knockout mice (ERKO) and ovariectomized (Ovx) rodents. In a model of 
cardiac ischemia-reperfusion, the mitochondria from male ERKO mice contained 
noticeable ultrastructural damage, and a reduced capacity to metabolize 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), indicating a decrease in 
respiratory chain function (79). These mice demonstrated fragmented, swollen 
mitochondria with a loss of matrix space, granular amorphous bodies, and ruptured 
cristae (79). In a similar examination of mitochondrial function in an ischemia-
reperfusion model, Ovx or E2-supplemented Ovx rats were compared to sham rats. The 
Ovx animals showed myocardial mitochondrial damage and a decrease in respiratory 
chain function (80). The ability of the respiratory chain to metabolize MTT was restored 
in Ovx rats fed a diet rich in phytoestrogens and was blocked by the classical ER 
antagonist ICI 182,780 (81). Likewise, mitochondrial structure was preserved in Ovx 
animals on the phytoestrogen diet and cotreatment with ICI 182,780 resulted in a loss of 
mitochondrial ultrastructural integrity (81). Inclusively, these studies suggest an 
important role for ER in maintaining mitochondrial structure and function in the 
ischemia-reperfusion model. 
Two studies examined the role of ERP in the cardiac tissues of knockout mice. 
PERKO mice develop hypertension beginning at approximately six months of age (82). 
These mice also demonstrate an increase in mortality and a rise in markers of heart 
failure. Additionally, ERP deletion leads to impairment ofCa2+ channels in chronic heart 
failure after a heart attack (83). Vascular smooth muscle cells and blood vessels from 
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BERKO mice have also demonstrated functional abnormalities such as abnormal vascular 
contraction (84). Unfortunately, the ultrastructure, function, and E2 responsiveness of 
cardiac mitochondria was not examined in either of these studies. 
The cytochrome P450 enzyme aromatase produces E2. A targeted disruption of 
exon 9 in this gene in Aromatase knockout mice (ArKO), leads to a deficiency in E2 
production (85). ArKO have been shown to have a lower diastolic blood pressure (BP) 
and higher heart rate (HR) than wild type control mice. The lower BP was proposed to 
be the result of lower vascular tone (85). In cultures of primary vascular smooth muscle 
cells from ArKO mice, apoptosis stimulated by TNF-a was increased and this 
upregulation was corrected by exogenous E2 exposure (86). To date, only one study has 
looked at the ultrastructure of the mitochondria in ArKO mice, and respiratory chain 
function has not been examined in these mice. Mitochondria from the cardiac interstitial 
cells of ArKO mice have been reported to be smaller in size compared to wild type 
animals and contain less organized tubular structure and less defined cristae. The 
deficient mitochondrial features observed were reversed by supplementation with E2 (87). 
Nuclear Respiratory Factor-l and Mitochondrial Regulation 
Nuclear Respiratory Factor-1 (NRF -1) was discovered in 1989 through 
examination of the cytochrome c promoter, which contained several transcription factor 
binding sites including a recognition site for NRF -1 (88). This 68 kDa protein contains a 
C-terminal transcriptional activation domain made up of clusters of hydrophobic aa such 
as glutamine (89,90). NRF-1 homodimerizes and binds to palindromic NRF-1 sites in the 
promoters of nuclear-encoded mitochondrial genes (91). NRF-1 can be phosphorylated 
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on serine residues in its N-terminal domain leading to an increase in DNA-binding and 
enhanced trans-activation function (92). NRF-l target genes have been predominantly 
identified by characterization of NRF -1 binding sites in the promoter regions of these 
genes. The major group of proteins first identified and mediated by NRF -1 includes the 
subunits of the five respiratory chain complexes. Additionally a number of other genes 
involved in the maintenance and function of the mitochondrion have been recognized 
including assembly factors for the respiratory apparatus, parts ofthe mtDNA 
transcription and replication machinery, mitochondrial and cytosolic enzymes of heme 
biosynthesis, and components of mitochondrial protein import (reviewed in (93)). Due to 
its ability to regulate the transcription of the nuclear-encoded mitochondrial transcription 
factors Tfam, TFBl, and TFB2, NRF-I has been suggested to playa key role in 
integrating nucleo-mitochondrial interactions (67). 
Several studies have shown a correlation between an increase in NRF -1 and an 
increase in mitochondrial biogenesis. For example, skeletal muscle has been shown to 
raise both NRF -1 and PGC-l a levels in response to exercise training (94). In agreement 
with this study, corresponding results were obtained in cultured myocytes subjected to 
calcium treatment which simulates exercise-induced mitochondrial biogenesis (95). 
HeLa cells depleted of mitochondria display an increase in NRF -1 and Tfam which is 
thought to be a compensatory response (96). Another study examining the regulation of 
Tfam in connection to a decrease in mtDNA found that methylation of the NRF-l binding 
site in the Tfam promoter significantly decreased activity of the promoter construct in 
transient transfection assays (97). 
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Perhaps the strongest evidence for a definitive link between NRF-1 and 
mitochondrial function and maintenance has come from the NRF -1 knockout mouse. A 
targeted disruption of the NRF-1 gene resulted in lethality between embryonic days 3.5 
and 6.5 in the homozygous null embryos (98). The null embryos displayed a reduced 
amount of mtDNA and a loss of mitochondrial membrane potential. The decrease in 
mtDNA was proposed to occur between fertilization and the blastocyst stage since 
heterozygous mothers exhibited normal levels of mtDNA (98). Thus, the decrease in 
mtDNA may result from a loss ofNRF-1-dependent mtDNA maintenance (98). A 
similar pattern of embryonic lethality is seen in Tfam knockout mice between embryonic 
day 8.8 to 10.5 (99). This indicates that the earlier lethality observed in the NRF-1 
knockout mice may be the result of a combination of loss of mtDNA maintenance and 
other NRF -1 dependent pathways (99). 
NRF -1 and Breast Cancer 
To date, there are no reports examining a role for NRF-1 in breast cancer. 
However, many scientists in the field of breast cancer research have performed 
micro array analysis in both breast cancer cell lines and breast cancer tissues. A closer 
examination of the data from these studies yielded some very interesting information. In 
order to mine data from previously published microarray data sets, two search methods 
were utilized. I used Oncomine (http://www.oncomine.org/mainlindex.jsp) to examine 
NRF -1 expression from microarray data sets in this database. I also searched available 
Affymetrix Geodata sets available on NCBI (http://www.ncbi.nlm.nih.gov). The first 
microarray data set examined involved a comparison of normal mammary epithelium 
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compared to two breast cancer cell lines, MDA-MB-436 (ERa and ERP negative (100)) 
and HCC 1954 (ERa positive (101)). In this study, the two cancer cells lines clearly 
expressed more NRF -1 compared to the normal mammary epithelium (Figure 2). 
A second microarray study examined the gene expression profiles of ER positive 
breast cancer cell lines treated with E2 for 24 h (102). The cell lines examined were 
MCF-7, T47-D, and BT-474 and the data was studied through NCBI Geo DataSets. In 
this microarray study, it is suggestive that NRF-l expression was slightly stimulated by 
E2 in the MCF-7 and T47-D but not the BT-474 cell lines (Figure 3). Since all three cell 
lines express ERa and ERP, the reason for a lack of responsiveness in the BT-474 cells is 
unknown. 
Moving to an in vivo model of breast cancer, mammary tumorigenesis was 
studied in an MMTV-neu mouse model by micro array profiling (103). In this set of 
experiments, gene expression profiles were examined in preneoplastic glands and tumors 
ofMMTV-neu mice (103). An increase in NRF-l expression is seen in the preneoplastic 
tissue compared to normal tissue and in the tumor compared to both the normal and 
preneoplastic tissue (Figure 4) (103). This increase in NRF-l expression corresponding 
to an increase in tumor progression suggests that upregulation of mitochondrial 
function/activity via NRF -1 may playa role in tumor progression. 
Expression patterns in human breast tumors reflect the trend demonstrated in 
breast cancer cell lines and the MMTV-neu mouse model, i.e., NRF-l expression is 
increased in higher tumor grades. In the first of two studies that I obtained by searching 
in the Oncomine database, gene expression profiles were examined in primary breast 
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Figure 2: NRF-l expression is increased in breast cancer cell lines compared to 
normal mammary epithelium. Affymetrix microarray analysis was used to evaluate 
gene expression levels in normal mammary epithelium compared to two breast cancer 
cell lines. The Red bars correspond with the increase in gene expression in a sample. 
This data set is available at: 
http://www.ncbi.nlm.nih.gov/projects/geo/gds/profileGraph.cgi? &dataset= ABoksz&datas 
et=UU3134$&labels=21246p Im5p 1 pIp 1 &grnax=7 .560000&gmin=6. 71 OOOO&title=GD 
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Figure 3: NRF-l expression is increased in response to E2 in some ER positive breast 
cancer cell lines. Cells were treated with E2 for 24 h and then examined by Affymetrix 
Microarray. The data is presented in relative expression units. The Red bars correspond 
with the increase in gene expression in a sample. This data set is available at: 
http://www.ncbi.nlm.nih.gov/projects/geo/gds/profileGraph.cgi? &dataset=zA3 0 POT c Y2 
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NORMAL PRENEOPLASTIC TUMOR 
MMTV-NEU 
Figure 4: NRF-l is increased in preneoplastic mammary tissue and mammary 
tumors in a MMTV -neu mouse model. Microarray analysis was performed to examine 
gene expression profiles in preneoplastic glands and tumors of MMTV -neu mice (l 03). 
The expression ofNRF-1 was extracted from the Affymetrix data sets available on NCB!. 
The Red bars correspond with the increase in gene expression in a sample. Pink bars 
represent expression levels that may have stray cross-hybridization and are therefore 
considered questionable. This data set is available at: 
http://www.ncbi.nlm.nih.gov/geo/gds/gdsbrowse.cgi?gds=1222 
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tumors from 117 patients using micro arrays (104). For micro array profiling, the tumors 
were divided into groups based on tumor grade. The NRF -1 expression data displays a 
positive association with increasing tumor grade with statistical significance between 
Grade 1 and Grade 3 (Figure 5A). The goal of a second large microarray study was to 
identify genes that would predict distant metastasis of lymph-node-negative primary 
breast cancer using 286 lymph-node-negative human breast tumor samples (105). I 
analyzed NRF-1 mRNA expression from these microarray data. My analysis showed that 
NRF-1 expression was significantly higher in ERa-positive compared to ERa-negative 
tumors (Figure 5B). 
E2-Induced Changes in Mitochondria in Normal Tissues 
Estrogens protective effects in the brain have been proposed to be mediated 
mainly through the mitochondria (106). In neuronal cells there is evidence that estrogens 
may promote cell viability by increasing the efficiency of respiration and maintaining 
ATP levels (107). Estrogens have been shown to increase Complex IV activity in the rat 
hippocampus (108), a pituitary cell line, GHtC l (109), whole brain mitochondria (106), 
and primary hippocampal neuron cultures (106). An increase in Complex IV activity was 
also accompanied by an increase in cytochrome c oxidase subunit IV (COIV) protein 
levels (106). Subsequent studies reveled the regulation of mitochondrial transcripts such 
as cytochrome c oxidase subunit I (COl), cytochrome c oxidase subunit II (COII), 
cytochrome c oxidase subunit III (COIII), NADH dehydrogenase subunit 1 (NDI), and 
the six ATPase subunits by E2 (108-112). More recently, the protein expression NRF-1 
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Figure 5: NRF-l mRNA expression is increased in higher tumor grades and in ER 
positive human breast tumors. (A) Gene expression profiles were examined in primary 
breast tumors from 117 patients using micro array (104). NRF-l mRNA expression was 
analyzed from the microarray data and displays a trend of increased NRF-l mRNA with 
increasing tumor grade. p< 0.003 between Grade 1 and Grade 3. (B) Gene-expression 
profiling was completed in 286 lymph-node-negative tumor samples to predict distant 
metastasis oflymph-node-negative primary breast cancer (113). NRF-l mRNA 
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tumors from 117 patients using microarrays (104). For micro array profiling, the tumors 
were divided into groups based on tumor grade. The NRF-l expression data displays a 
positive association with increasing tumor grade with statistical significance between 
Grade 1 and Grade 3 (Figure 5A). The goal of a second large micro array study was to 
identify genes that would predict distant metastasis of lymph-node-negative primary 
breast cancer using 286 lymph-node-negative human breast tumor samples (105). I 
analyzed NRF -1 mRNA expression from these micro array data. My analysis showed that 
NRF -1 expression was significantly higher in ERa-positive compared to ERa-negative 
tumors (Figure 5B). 
fu-1nduced Changes in Mitochondria in Normal Tissues 
Estrogens protective effects in the brain have been proposed to be mediated 
mainly through the mitochondria (106). In neuronal cells there is evidence that estrogens 
may promote cell viability by increasing the efficiency of respiration and maintaining 
ATP levels (107). Estrogens have been shown to increase Complex IV activity in the rat 
hippocampus (108), a pituitary cell line, GlLtC I (109), whole brain mitochondria (106), 
and primary hippocampal neuron cultures (106). An increase in Complex IV activity was 
also accompanied by an increase in cytochrome c oxidase subunit IV (COIV) protein 
levels (106). Subsequent studies reveled the regulation of mitochondrial transcripts such 
as cytochrome c oxidase subunit I (COl), cytochrome c oxidase subunit II (COIl), 
cytochrome c oxidase subunit III (COllI), NADH dehydrogenase subunit 1 (NDI), and 
the six ATPase subunits by E2 (108-112). More recently, the protein expression NRF-l 
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Figure 5: NRF-l mRNA expression is increased in higher tumor grades and in ER 
positive human breast tumors. (A) Gene expression profiles were examined in primary 
breast tumors from 117 patients using micro array (104). NRF-l mRNA expression was 
analyzed from the micro array data and displays a trend of increased NRF -1 mRNA with 
increasing tumor grade. p< 0.003 between Grade 1 and Grade 3. (B) Gene-expression 
profiling was completed in 286 lymph-node-negative tumor samples to predict distant 
metastasis oflymph-node-negative primary breast cancer (113). NRF-l mRNA 
expression was analyze from the microarray data and displays an increase in ER positive 
tumors. p<0.037 
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2 weeks (114). These blood vessels also displayed increased expression of Cal and 
COIV, an increase in Complex IV activity, and an ICI 182,780 inhibited increase in 
Complex IV activity (114). In agreement with this information, previous studies reported 
that the respiratory function of mitochondria from whole brain was increased by 
treatment with E2 in vivo as measured by oxygen consumption (106). However, the 
mechanism of these effects, including the E2-induced increase in Complex IV activity 
and protein, has not been described. 
When NRF -1 expression was examined in normal tissues, breast tissue had a 
higher expression ofNRF-1 compared to the other tissues examined with the exception of 
lung (115). NRF-1 expression was shown to be responsive to E2 treatment in normal 
uterus in microarray experiments. Using an Affymetrix Geo DataSet from Moggs et aI, 
NRF -1 expression was demonstrated in response to a single injection of 400 ).lg/kg E2 in 
immature 19 to 20 day old Alpk:APfCD-1 mice. Alpk:APfCD-1 mice are 
immunodeficient due to a lack of alpha protein kinase 1. Microarray analysis was 
performed to analyze gene expression profiles at varying time points (116). NRF-1 
mRNA expression is increased in E2 treated samples as soon as 2 h after exposure to E2. 
This response tapers off by 24 h (Figure 8). 
Electron microscopy has been used to examine the structure and number of 
mitochondria as previously discussed in the case of the ERKO rats. Changes in 
mitochondrial structure in response to E2 have been reported in MCF-7 cells, mammary 
gland, and uterine smooth muscle. MCF-7 cells were examined by transmission electron 
microscopy for their response to E2 (10 nM) over time (117). It was reported that when 
MCF-7 cells were cultured in 10% Fetal Calf Serum (FCS) containing media, the cells 
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had normal round mitochondria that were large and clear. However, after both 5 and 15 
days of culture in media containing 10% dextran coated charcoal (DCC) treated FCS 
(DCC-FCS), the cells appeared smaller with small dark mitochondria. After 4 days in E2 
containing DCC-FCS, the mitochondria were again large and clear with thin and 
numerous cristae. A similar effect was seen in the ER positive T47D breast cancer cells, 
but not the ER null BT20 breast cancer cells (117). The results ofthese experiments 
support a role for ER in the maintenance of mitochondrial structure. These results also 
agree with the observations recorded in Ovx mice, in which, a lack of estrogen lead to a 
loss of matrix area and reduced mitochondrial respiratory chain function (MRC) 
(80,114). 
A study examining the effects of E2 and progesterone in Ovx mice used electron 
microscopy to examine the structure of cells in the parenchyma and blood vessels of the 
mammary gland (118). While examining the epithelial cells of the mammary ducts and 
buds, it was observed that the Ovx and progesterone treated mice displayed a small 
number of mitochondria. However, in E2 and E2+Progesterone treated Ovx mice, there 
were numerous mitochondria (118). This data suggests a role for E2 in increasing the 
number of mitochondria in the cell. 
The fine structure of the uterine smooth muscle was examined in Ovx rats treated 
with a single injection ofE2 and sacrificed at 6, 12,24,48, 72, and 96 h. No change in 
the mitochondria was noted at 6 and 12 h. However, an increase in the number of 
mitochondria was seen between 24 and 48 h followed by an increase in mitochondrial 
size at 72 and 96 h (119,120). As with the previously discussed study in mammary 
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Figure 6: NRF-l expression in normal tissue. Gene expression patterns were 
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Figure 7: NRF -1 expression in uterine tissue in response to E20 Gene expression 
patterns were examined in response to a single injection of 400 flg/kg E2 in immature 19 
to 20 day old Alpk:APfCD-1 mice. Microarray analysis was performed to examine gene 
expression profiles at varying time points (116). The Red bars correspond with an 




gland, the results of the examination of the uterine smooth muscle suggest a role for E2 in 
increasing mitochondrial number. 
Inclusively, from the aforementioned studies it is clear that E2 has an impact on 
the number and morphology of mitochondria in several cells types. However, the 
mechanisms guiding this change have not yet been determined. 
Goals of the Project 
The overall goal of this project was to test the hypothesis that the previously 
reported E2-induced increases in mitochondrial activity and mitochondrial subunit mRNA 
expression are a result of an increase in the transcription of NRF -1 mediated directly by 
ER in response to E2. In addition, I hypothesized that this upregulation ofNRF-1 by ER 
is mediated directly through an ERE in the NRF-1 promoter. My experimental design 
included cloning of the promoter region ofNRF-1 into a luciferase reporter vector and 
testing the responsiveness of regions with and without the ERE and a mutated ERE to 
examine the contribution of the ERE to NRF-l induced expression. 
Since SERMs can have differential effects based on the coactivator expression 
patterns in each cell type and gene context, e.g., the ERE sequence and adjacent 
transcription factor binding sites, the expression ofNRF-l was examined in response to 
the SERMs 4-0HT and RAL. Additionally, since NRF-l is known to be important to 
cardiovascular function, Human Umbilical Vein Endothelial Cells (HUVEC) were treated 
with E2, 4-0HT, and RAL and their response examined. Diesel Exhaust Particle Extracts 
(DEPE), known antagonists of genomic estrogen responses in MCF -7 cells were used in 
conjunction with E2, 4-0HT, and RAL to determine their impact on NRF-1 expression 
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due to the known risk increase in cardiovascular disease in people living in high traffic 
areas (121). Lastly, to further extend these studies, a known phytoestrogen, resveratrol 
(122,123), was tested for its ability to induce NRF-1 and protect against DEPE induced 
antagonism of the NRF-1 gene. Resveratrol has been previously reported to have 
cardioprotective effects (124,125). Here I tested the hypothesis that resveratrol would 
protect human umbilical vein endothelial cells against DEPE- induced damage. 
Inclusively, these studies have provided more information on how NRF-1 is regulated by 
E2, SERMs, an environmental pollutant, and a phytoestrogen. 
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CHAPTER II 
REGULATION OF NUCLEAR RESPIRATORY FACTOR-1 EXPRESSION BY 17~­
ESTRADIOL 
INTRODUCTION 
Experimental evidence demonstrates that liver and brain mitochondria of normal, 
but not Ovx, female rats generate less ROS and have higher respiratory potential resulting 
from decreased oxidative damage (126). The decrease in ROS and higher respiratory 
potential may help explain the observed increased longevity of females in most 
mammalian species (127). Although the sex differences in mitochondrial function are 
likely mediated by estrogens, the mechanism(s) underlying these effects remain ill-
defined. Therefore, a goal in the present study was to elucidate one of the pathways that 
may contribute to the observed estrogen-regulated increase in mitochondrial function. 
In addition to the already discussed genomic effects of ER that occur within 3-6 h 
after estrogen administration, ER has rapid, membrane-initiated, non-genomic effects that 
take place within seconds-minutes of estrogen treatment (reviewed in (128,129)). In 
order to study the mechanism of ER induced changes in NRF -1 expression, the 
contribution of non-genomic ER must be considered. Non-genomic effects of ER have 
been best characterized in endothelial cells in which E2 rapidly inhibits calcium influx 
(130), increases intracellular Ca++ (131) and cAMP (132), and stimulates NO release 
resulting in vasodilation (133), and thus accounting, in part for the observed 
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cardioprotective effects of estrogens. ER is known to mediate non-genomic effects 
through the Mitogen Activated Protein Kinase (MAP Kinase) pathway in addition to 
genomic effects in MCF-7 cells (134,135). The membrane-associated ERs that mediate 
these non-genomic effects are transcribed from the same messages used to generate 
nuclear ERa and ER~, and are inhibited by the ER antagonist ICI 182,780 (136). 
Membrane-associated ER conveys these rapid intracellular effects by activating G-
coupled proteins, adenyl ate cyclase production, and inositol phosphate production (136). 
By activating networks including the MAPK and phosphoinositide-3 (PI3) Kinase 
pathways, non-genomic ER rapidly induces a number of changes within the cell 
including changes in gene expression through phosphorylation of transcription factors 
and coregulators (129,137). 
As previously discussed, NRF -1 is upregulated in cerebral blood vessels of Ovx 
rats chronically treated with E2, suggesting that estrogen may regulate NRF-l 
transcription (114). Coordination of the expression of the mitochondrial and nuclear-
encoded genes required for mitochondrial biogenesis and function has been proposed to 
be mediated by the ability of hormone receptors present within the mitochondria to 
induce expression of genes encoded in the mtDNA (138). However, this hypothesis has 
been debated in the literature. Here, I tested the hypothesis that the E2-induced effects 
such as upregulation of mitochondrial activity and an increase in mitochondrial subunit 
mRNA expression previously demonstrated are a result of the upregulation ofNRF-l by 
ER in response to E2. 
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MATERIALS AND METHODS 
Cell Culture and Treatment Description 
MCF-7 breast adenocarcinoma, H1793 lung adenocarcinoma, and MCF-I0A non-
tumorigenic epithelial cell were purchased from the American Type Culture Collection 
(ATCC). According to the ATCC, MCF-7 cells were derived from the pleural effusion of 
a 69 year old female with breast cancer. MCF-7 cells express both ERa and ER~ in 
equivalent amounts as our lab has previously reported (32). MCF -7 cells were 
maintained in Iscove's Modified Eagle's Medium (lMEM) supplemented with 10% fetal 
bovine serum (FBS) and 1 % penicillin/streptomycin. For all treatments, MCF-7 cells 
were placed in phenol red free IMEM supplemented with 10% charcoal stripped (CCS)-
FBS for 72-96 h prior to treatment. 
NCI-HI793 cells were derived from the non-small cell lung adenocarcinoma of a 
52 year old non-smoking female, according to the ATCC. These cells express 
predominantly ER~ with approximately 60% less ERa than ER~ (32). H1793 cells were 
maintained in media containing 50% Dulbecco's Modified Eagle's Medium (DMEM) and 
50% FK-12 medium supplemented with 0.005 mg/ml insulin, 0.01 mg/ml transferrin, 30 
nM sodium selenite, 10 nM hydrocortisone, 10 nM 17~-estradiol, 10 mM HEPES, 2 mM 
L-glutamine, 5% FBS, and 1 % penicillin/streptomycin. Prior to treatment the cells were 
placed in DMEM:FK-12 media supplemented with 30 nM sodium selenite, 10 mM 
HEPES, 2 mM L-glutamine, 5% CCS-FBS, and 1 % penicillin/streptomycin for 48 hours. 
MCF-IOA cells are a "normal" breast non-tumorigenic epithelial cell line that was 
originally derived from a subcutaneous mastectomy and spontaneously immortalized 
(139). They express low levels ofER~ and no ERa (139). MCF-IOA cells were 
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maintained in media consisting of 50% DMEM and 50% FK-12 medium supplemented 
with 5% horse serum, 20 ng of EGF per ml, 10 )lg of insulin per ml, and 0.5 )lg of 
hydrocortisone per ml of media. For all treatments, MCF-lOA cells were placed in 
phenol red free IMEM supplemented with 10% charcoal stripped (CCS)-FBS for 48 h 
prior to treatment. 
RNA Isolation, RT-PCR and Quantitative Real Time RT-PCR (QRT-PCR) 
RNA was extracted using Trizol (Invitrogen) according to the manufacturer's 
protocol. RNA concentration was determined, and 2 )lg of RNA was used to generate 
cDNA. RNA was subjected to a DNAse I digestion at 37°C for the PCR analysis using 
the COl and NDI mitochondrial primers. The High Capacity cDNA archive kit (PE 
Applied Biosystems) was used to reverse transcribe total RNA using random hexamers. 
Taqman primers and probes for NRF-l, Tfam, and the control gene, 18S rRNA, were 
purchased as Assays-on-Demand™ Gene Expression Products (PE Applied Biosystems). 
Measurement of COl, NDI, and 18S using SYBR Green (PE Applied Biosystems) was 
performed using previously published primer sequences for COl and NDI listed in Table 
1 (140). The expression of each target gene was determined in triplicate and normalized 
using 18S. QRT-PCR for NRF-l and 18S Assays-on-Demand was performed in the ABI 
PRISM 7900 SDS 2.1 (PE Applied Biosystems) using relative quantification with 
standard thermal cycler conditions. QRT-PCR for COl, NDI, and 18S was also 
performed in the ABI PRISM 7900 SDS 2.1 using absolute quantification. Analysis and 
fold differences were determined using the comparative CT method. Fold change was 
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calculated from the L1L1CT values with the fonnula 2"'~LlCT and data are presented as 
relative to expression in EtOH-treated samples unless otherwise stated. 
Transient Transfection of MCF-IOA Cells 
MCF-I0A cells were grown to 60% confluency in 6-well plates. Prior to 
transfection, MCF-I0A cells were placed in IMEM with 10% CCS-FBS. The cells were 
transfected with lOng of pCMV -ERa (provided by B.s. Katzenellenbogen) using 
FuGene 6 at a 3:1 FuGene 6 to DNA ratio. Twenty-four h post-transfection, the cells 
were treated for 4 h with E2 and the mRNA harvested as described in the previous 
section. 
Protein Isolation and Western Blot Analysis 
Whole cell extracts (WCE) were collected in 300 ilL modified 
Radioimmunoprecipitation (RIPA) buffer 50 mM Tris-HCl, pH 7.4; 1% Nonevent P-40; 
0.25% Na-deoxycholate; 150 mM NaCl; 1 mM EDTA; 1 mM phenylmethylsulfonyl 
fluoride (PMSF); aprotinin, leupeptin and pepstatin, each at 1 Ilg/ml; 1 mM Na3 V04; 1 
mM NaF. To obtain membrane preparations, the cells were collected in TSE Buffer (25 
mM Tris, 250 mM Sucrose, ImM EDTA, and 1 X protease inhibitors (Roche). Cells 
were lysed, subjected to centrifugation at 600 rpm for 10 min, and the supernatant 
collected and subject to centrifugation for 20 min at 100,000 rpm. The pellet was 
resuspended in TSE Buffer. Protein concentrations were detennined using the 
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Primer Name Primer Sequence 
COl Forward 5'- TACGTTGTAGCCCACTTCCACT -3' 
COl Reverse 5'- GGAT AGGCCGAGAAAGTGTTGT -3' 
NDI Forward 5'- ACACTAGCAGAGACCAACCGAA -3' 
NDI Reverse 5'- GGGAGAGTGCGTCATATGTTGT -3' 
Table 1: SYBR Green Primer Sequences for QRT -peR. All primers were used at a 
concentration of 5 IlM with standard cycling conditions. 
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resuspended in TSE Buffer. Protein concentrations were determined using the Bio-Rad 
DC Protein Assay. 
Thirty micrograms of protein were separated on 8% or 15% SDS-PAGE gel using 
a BioRad casting and electrophoresis system. The protein was transferred onto a PVDF 
membrane (BioRad) at 100 volts for 1 h for NRF-1 detection and 0.5 h for COl and 
cytochrome c oxidase subunit IV (COIV) detection. The blots were blocked in 5% dry 
milk in TBS-Tween (20 mM Tris, 137 mM NaCI, and 0.1% Tween) and probed with 
either the polyclonal NRF -1 antibody (Rockland Scientific), monoclonal COl antibody 
(MitoScience), or monoclonal COIV antibody (MitoScience). The NRF-l blots were 
stripped by incubation in Stripping Buffer (100 mM ~-mercaptoethanol, 2% sodium 
dodecyl sulfate, 62.5 mM Tris-HCI, pH 6.7) at 50°C for 30 minutes with intermittent 
agitation. The membranes were then washed in TBS-Tween and re-blocked in 5% milk 
prior to incubation with a-tubulin (Neomarkers) as a loading control. Protein Disulfide 
Isomerase (PDI) (Sigma) was used as a loading control for COl and COIV. A secondary 
horse radish peroxidase (HRP) conjugated anti-rabbit or anti-mouse antibody (Pierce) 
was used followed by treatment with PicoWest Chemiluminescent Reagent (Pierce). 
Kodak Film (Eastman Kodak) was used for image capture followed by development in a 
Kodak X-OMAT Film Processor. 
Un-Sean-It (Silk Scientific) was used to quantitate the integrated optical densities 
(lOD) for each band. The IOD for NRF-l was divided by the concordant a-tubulin or 
PDI in the same blot. The EtOH value was set to 1 in all hormone treatment experiments. 
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Mitochondrial Biogenesis 
Two methods were used to examine mitochondrial biogenesis, semi-quantitative 
analysis ofmtDNA copy number and oxygen (02) consumption. For semi-quantitative 
PCR, MCF-7 cells were plated at 50% confluency in a 12-well plate. The cells were 
placed in phenol free IMEM containing 10% CCS-FBS for 72 h followed by treatment 
with 10 nM E2 for 24, 48, and 72 h. The cells were harvested using the Wizard Genomic 
DNA Isolation Kit (Promega). 1 ng of genomic DNA was subject to PCR for a 250 bp 
segment of mtDNA and a 150 bp segment of 18S for 27 cycles and the product was 
resolved on a 2% agarose gel. Semi-quantitative PCR analysis was performed using 
GoTaq Polymerase from Promega. Each reaction included IX Green GoTaq Flexi 
Buffer, 1.5 mM MgCh, 0.2 mM of each dNTP, 1 /lM mtDNA forward primer, 1 /lM 
mtDNA reverse primer, 1 /lM 18S forward primer, 1 /lM 18S reverse primer, 1.25 units 
GoTaq, and nuclease free water to a total volume of20 uL. The PCR primers, designed 
using Primer3, are shown in Table 2. Gel images were scanned and Un-Scan-It was used 
to quantitate the 10D for each band. The 10D for mtDNA was divided by the concordant 
18S in each lane. The EtOH value was set to 1 in all hormone treatment experiments. 
O2 consumption was measured using a Strathkelvin Instruments Electrode. For 
these experiments, MCF-7 cells were propagated as described previously in 150 mm 
cultured dishes. Upon reaching 50% confluency, the cells were placed in phenol red-free 
IMEM with 10% CCS-FBS for 48 h. Subsequently, a final concentration of 10 nM E2 
was added to the cells for 2, 4, or 6 d. The media was replaced every 48 h with fresh 
IMEM containing 10% CCS-FBS and EtOH or 10 nM E2 where appropriate. Prior to the 
O2 consumption measurements, cells were removed from the plates and cell number was 
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Primer Name Primer Sequence 
mtDNA Forward 5'-TACCCATCATAATCGGAGGC-3' 
mtDNA Reverse 5'-TGAAA TTGATGGCCCCTAAG-3' 
I8S Forward 5' -GT AACCCGTTGAACCCCATT -3' 
I8S Reverse 5' -CCATCCAA TCGGTAGTAGCG-3' 
Table 2: peR Primers Used for Mitochondrial Biogenesis Experiments 
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ascertained using trypan blue exclusion to identify viable cells. O2 consumption rates 
were measured using 5 x 106 cells suspended in a total volume of 0.5 ml of phenol red-
free IMEM medium containing 10% CCS-FBS. Readings were collected for 10 min or 
until all O2 had been consumed. Rates of O2 consumption are calculated using a software 
package: 782 System ver. 3.0 (Strathkelvin Instruments). 
siRNA Knockdown of ERa, ER6, and NRF-l 
siRNA knockdown of ERa and ERP was performed in MCF-7 cells using siRNA 
duplexes obtained from either New England Biolabs (ERa) or Millipore (ERP). Both 
siRNAs were transfected using TransPass™ R1 (New England Biolabs). MCF-7 cells 
were cultured in 12-well plates until 50% confluent. 6 /-ll of TransPass™ R1 was added 
to 100 /-ll ofOPTI-MEM. A final concentration of25 nM of ERa and 100 nM ofERP 
was added to the diluted transfection reagent and incubated for 20 min. 500 /-ll of IMEM 
containing 10% CCS-FBS was added to the transfection mixture. The MCF-7 cells were 
then washed twice with IMEM containing 10% CCS-FBS and the transfection mixture 
was added to the cells. The cells were incubated with the transfection mixture for 24 h, 
and then the media was replaced with IMEM containing 10% CCS-FBS. The cells were 
incubated another 48 h, and they were treated with 10 nM E2 or EtOH and RNA or 
protein harvested. 
MCF-7 cells were cultured in 6-well plates in order to generate RNA, WCE, and 
genomic DNA examining the effect of siRNA knockdown of NRF -1. Upon reaching 
60% confluency, the growth media was replaced with IMEM containing 10% CCS-FBS 
for the transfection. 8 /-ll of siRNA targeting NRF -1 (Santa Cruz) or Control siRNA 
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(Santa Cruz) was diluted in 100 ~L ofOPTI-MEM. In a separate tube, 8 ~l of siRNA 
Transfection Reagent (Santa Cruz) was diluted in 100 ~L ofOPTI-MEM. The siRNA 
and Transfection Reagent Solutions were combined and incubated at room temperature 
for 45 min. For each transfection, 0.8 ml ofIMEM containing 10% CCS-FBS was added 
to the transfection mixture. The media was removed from the cells and the transfection 
complex added. After 24 h, the media was replaced with fresh IMEM containing 10% 
CCS-FBS and incubated another 24 h. A total of 48 h post-transfection, the cells were 
treated with 10 nM E2 for 48 h. 
Statistics 
Statistical analyses were performed using GraphPad Prism (San Diego, CA.). 
Two-tailed Student's t tests were used for the pair-wise comparison of experimental 
groups. Statistical significance was defined at 2: 95% confidence interval (95% CI) or P S 
0.05. Bar graphs represent the mean ± standard error of the mean (SEM) for the number 
of independent experiments indicated in each figure legend. 
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RESULTS 
fu-Induced NRF-l Transcription is Mediated by Genomic ER 
NRF -1 protein expression was reported to be increased in the cerebral blood 
vessels ofOvx rats after two weeks ofE2 treatment (114). However, this study did not 
examine whether this E2 effect was a primary estrogen response, i.e., mediated directly 
by E2 at the transcription level, or a result of a long term alteration in gene expression 
patterns, i.e., a secondary or tertiary response, due to E2 exposure. To determine ifNRF-
1 is a direct E2 target gene, estrogen-responsive H1793 human lung adenocarcinoma (32) 
and MCF-7 human breast adenocarcinoma (141) cells were treated with E2 and NRF-1 
expression measured by QRT-PCR. NRF-1 mRNA expression was increased by E2 
treatment in both cell lines with a more robust induction in MCF-7 compared to H1793 
cells. MCF-7 cells displayed a significant increase in NRF-1 mRNA at 1 h after E2 
treatment, and this response peaked at 5-fold induction at 4 h (Figure SA). H1793 cells 
also displayed a significant increase in NRF -1 mRNA at 1 h after E2 treatment and this 
response peaked at 2.5-fold at 2 h (Figure SB). H1793 cells showed an apparent second 
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Figure 8: E2 treatment induces an increase in NRF-l mRNA expression in MCF-7 
and H1793 cells. (A) MCF-7 and (B) H1793 cells were treated with EtOH or 10 nM E2 
for the times indicated. The total mRNA was isolated and QRT-PCR was performed as 
described in Material and Methods. Values are the average of 3-6 separate experiments ± 
SEM. a= P< 0.05 compared to EtOH. 
41 
ICI 182,780 is a well-established antagonist of genomic ER that decreases nuclear 
ERa concentration (142), prevents coactivator recruitment (143), inhibits dimerization of 
the receptor (144), and enhances ERa, but not ERP, proteosomal degradation (143). To 
determine if the E2-induced increase in NRF-l is directly mediated by ER, MCF-7 and 
H1793 cells were pre-treated for 6 h with 100 nM ICI 182,780 prior to treatment with 10 
nM E2. This pre-incubation time was selected because previous studies had demonstrated 
a ~80% decrease in ERa protein levels as early as 4 h post-treatment with ICI 182,780 
(143). ICI 182,780 blocked the E2-induced increase in NRF-l mRNA, indicating that 
ER mediated this response (Figure 9A and B). 
In addition to treatment with ICI-182,780, MCF-7 cells were treated with a 
Proteolysis Targeting Chimeric Molecule (Protac) known as E2-Penta (Figure lOA) 
(145). In general, Protacs are hybrid compounds constructed of an E3 ubiqitin ligase 
conjugated to a targeting molecule (146). In this case, E2 has been conjugated to an E3 
ubiquitin ligase. Binding of the E2-Penta Compound (EPC) to ER results in targeting of 
ER to the Proteaosome. Treatment with the EPC inhibited the E2-induced increase in 
MCF-7 cells further indicating that ER mediates this response (Figure lOB). 
NRF-l is a Primary Estrogen-Responsive Gene Mediated by Genomic ER 
The transcriptional inhibitor Actinomycin D (Act D) and the protein synthesis 
inhibitor cycloheximide (CHX) were used to determine if the E2-ER mediated increase in 
NRF -1 was a direct effect of ER at the genomic level or required synthesis of a secondary 
estrogen-responsive protein. Notably, Act D, but not CHX, inhibited the E2-induced 
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Figure 9: ICI 182,780 blocks the E2-induced increase in NRF -1 mRNA in MCF-7 
and H1793 cells. (A) MCF-7 and (B) H1793 cells were treated with 100 nM ICI 
182,780 or EtOH for 6 h prior to treatment with 10 nM E2 for 4 h. The total mRNA was 
isolated and QRT-PCR was performed as described in Material and Methods. Values are 
the average of 3-6 separate experiments ± SEM. a = P< 0.05 compared to EtOH; 
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Figure 10: EPC blocks the E2-induced increase in NRF-1 mRNA in MCF-7 cells. 
MCF-7 cells were pre-treated with 25 ).lM EPC for 48 h followed by the addition of either 
EtOH or 10 nM E2 for 4 h. The total mRNA was isolated and QRT-PCR was performed 
as described in Material and Methods. Values are the average of 3 -4 separate 
experiments ± SEM. a = P< 0.05 compared to EtOH; b = P< 0.05 compared to E2 
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increase in NRF-1 mRNA (Figure 11A), indicating that the de novo expression of an E2-
induced protein was not required for increased NRF-1 transcription. I concluded that 
NRF -1 is a primary E2-responsive gene. 
To determine if the E2-induced increase in NRF-I mRNA is mediated by non-
genomic ER activity, MCF-7 cells were pretreated for 1 h with the PI3 Kinase and MAP 
kinase kinase (MEK) inhibitors Wortmannin and PD98059, respectively. Neither 
inhibitor altered the E2-induced increase in NRF-1 mRNA (Figure lIB). This indicates 
that the E2-induced increase in NRF-l is mediated by genomic actions ofER and not its 
nongenomic functions through the PI3K1 Akt and MAPK pathways. 
Both ERa and ERB Increase NRF -1 Transcription 
Since both ERa and ER~ proteins are expressed in MCF-7 (32,147) and H1793 
cells (32), the observed ER-dependent upregulation ofNRF-1 by E2 could be mediated by 
both or either ER subtype. To test the ER subtype specificity of the E2-induced increase 
in NRF-1 in MCF-7 and H1793 cells, cells were treated with ERa and ER~ selective 
agonists, propyl pyrazole triol (PPT) (148) and diarylpropionitrile (DPN) (149), 
respectively. PPT or DPN alone yielded ~ 50% of the E2 response in MCF-7 (Figure 
12A). The increase in NRF-1 mRNA induced by a combination ofPPT and DPN was 
not statistically different from the E2-stimulated increase in NRF -1 transcription perhaps 
due to the large error bars. Together, these data indicate that both subtypes ofER 
contribute equally to NRF -1 activation. Treatment with an ER~ selective antagonist, the 
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Figure 11: E2-induced NRF-l transcription is mediated by genomic ER. (A) MCF-7 
cells were pretreated with 10 J..lg/ml Act D or CHX for 1 h followed by 4 hs of 10 nM E2. 
(B) MCF-7 cells were pre-treated with 50 J..lM PD98059 or 50 nM Wortmannin for 1 h 
prior to incubation with 10 nM E2 for 4 h. The total mRNA was isolated following 
treatment and QRT-PCR was performed as described in Material and Methods. Values 
are the average of 3 separate experiments ± SEM. a = P< 0.05 compared to EtOH; b = 























PPT DPN PPT+DPN R,R-THC+E2 
a 
PPT DPN R,R-THC+ E2 
Figure 12: Both ERa and ER~ up regulate NRF-l gene transcription. (A) MCF-7 or 
(B) H1793 cells were treated with EtOH, 10 nM E2, 10 nM DPN, 10 nM PPT, 10 nM 
R,R-THC, or both PPT and DPN for 4 h. The total mRNA was isolated following 
treatment and QRT-PCR was performed as described in Material and Methods. Values 
are the average of 3 separate experiments ± SEM. a = P< 0.05 compared to EtOH; 
b=P<0.05 compared to E2 
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MCF-7 cells resulted in a ~50% repression of the E2-induced increase in NRF-1 mRNA 
(Figure 12A). Our lab previously reported that the MCF-7 cells we use express 
equivalent amounts of ERa and ER~ (32). The PPT, DPN, and R,R-THC data support an 
equal contribution for each ER subtype in the E2-regulation ofNRF-l in MCF-7 cells. In 
contrast, PPT had no significant effect on NRF-1 expression in H1793 cells. Importantly, 
DPN induced an increase in NRF-1 mRNA in H1793, and co-treatment ofH1793 with E2 
and R,R-THC inhibited NRF-1 expression (Figure 12B). These data indicate that ER~ 
mediates E2-stimulated NRF -1 expression in H 1793 and are in agreement with the 
observation that ER~ protein expression is more than twice that of ERa in H1793 cells 
(32). 
MCF -1 OA cells are a non-tumorogenic mammary epithelial cell line that express 
ER~ but not ERa (139). To further explore the ER subtype contribution to NRF-1 
activation, MCF-10A cells were treated with E2 in the presence or absence of transiently 
transfected ERa (Figure l3). Treatment with E2 resulted in a small but significant 
increase in NRF-1 mRNA expression. Transfection with ERa alone resulted in an 
increase in basal NRF-1 mRNA expression equal to the increase stimulated by E2 
treatment in the untransfected cells. This could be the result of residual hormones in the 
media activating the large amount of ERa now present in the cell. When ERa 
transfected MCF-10A cells were treated with E2, a 6-fold induction in NRF-1 mRNA was 
observed. These data indicate that both ERa and ER~ contribute to the E2-induction of 
NRF-1 mRNA expression in MCF-10A cells. 
From the MCF-7, H1793, and MCF-lOA experiments I concluded that the 














EtOH E2 ERa ERa+E2 
Figure 13: Both ERa and ER~ up regulate NRF-l gene transcription in MCF-IOA 
cells. MCF -1 OA or MCF -1 OA cells transiently transfected with ERa were treated with 
EtOH or 10 nM E2 for 4 h. The total mRNA was isolated following treatment and QRT-
PCR was performed as described in Material and Methods. Values are the average of 3 
separate experiments ± SEM. a = P< 0.05 compared to EtOH; b=P<0.05 compared to E2 
alone or ERa alone 
49 
siRNA Knockdown of ERa and ERB Inhibits the E2-induced Increase in NRF-l 
MCF -7 cells were transfected with siRNA targeting ERa or ER~ in order to 
further examine the subtype contribution to the E2-induced increase in NRF-l. 
Transfection ofMCF-7 cells with siRNA targeting ERa lead to approximately a 50% 
decrease in both ERa mRNA and protein production (Figure 14). Subsequently, the 
ERa-siRNA transfected cells were treated for 4 h with E2 and NRF-l mRNA levels 
examined. In the presence of the siRNA targeting ERa, no increase in NRF -1 mRNA 
was seen with E2 treatment (Figure 15). In a similar manner, MCF-7 cells were 
transfected with siRNA targeting ER~. ER~ was decreased by 30% at the mRNA levels 
(Figure 16). Knockdown ofER~ resulted in a loss of the E2-mediated increase in NRF-l 
mRNA (Figure 17). The observed significant decrease in NRF -1 in response to 
knockdown of both ERa and ER~ suggests that heterodimers of ERa/ER~ may be 







































Figure 14: siRNA knockdown of ERa. (A) MCF-7 cells were not transfected or 
transfected with Control siRNA or siRNA targeting ERa. The total mRNA was isolated 
following treatment and QRT-PCR was performed as described in Material and Methods. 
Values are the average of 3-6 separate experiments ± SEM. (B) A representative western 
blot ofMCF-7 cells transfected with Control siRNA or siRNA targeting ERa is shown 
above a summary graph of the data normalized to a-tubulin in the same blot. Values are 
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Figure 15: siRNA knockdown of ERa. inhibits the Ez-induced increase in NRF-l 
mRNA. MCF-7 cells were not transfected or transfected with Control siRNA (treated 
with EtOH or E2) or siRNA targeting ERa (treated with or without E2)' The cells were 
treated for 4 hand QRT-PCR was performed for NRF-l. The total mRNA was isolated 
following treatment and QRT-PCR was performed as described in Material and Methods. 
Values are the average of 3-6 separate experiments ± SEM. a = P< 0.05 ,compared to 
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Figure 16: siRNA knockdown of ERf3. (A) MCF-7 cells wen~ not transfected or 
transfected with Control siRNA or siRNA targeting ERp. The total mRNA was isolated 
following treatment and QRT-PCR was performed as described in Material and Methods. 
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Figure 17: siRNA knockdown ofER~ inhibits the E2-induced increase in NRF-l 
mRNA. MCF -7 cells were not transfected or transfected with Control siRNA (treated 
with EtOH or E2) or siRNA targeting ERa (treated with or without E2)' The cells were 
treated for 4 hand QRT-PCR was performed for NRF-l. The total mRNA was isolated 
following treatment and QRT-PCR was performed as described in Material and Methods. 
Values are the average of 3-6 separate experiments ± SEM. a == P< 0.05 compared to 
Control siRNA; b = P< 0.05 compared to E2 
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NRF -1 Protein Expression is Increased by E1 
Western blot analysis ofNRF-l protein expression after E2 treatment revealed a 
time-dependent increase in NRF-l in MCF-7 cells which was significant above control at 
24 h ofE2 treatment (Figure 18). These results agree with the increase seen in NRF-l 
mRNA expression with E2 treatment but are delayed in time, as seen for other E2-target 
genes (151). 
The Expression of Tfam. COl. and NDI mRNAs are Increased by E1 
The expression of Tfam was analyzed by QRT-PCR to determine if the E2-
induced increase in NRF -1 resulted in a downstream upregulation in the transcription of a 
NRF-l target gene, nuclear-encoded TFAM. Subsequently, QRT-PCR was used to 
examine an induction in the expression of two mitochondrial-encoded mRNAs, COl and 
NDI, which are targets of Tfam. Tfam mRNA was increased 12-72 h after E2 treatment 
(Figure 19A) and ICI 182,780 inhibited this response (Figure 19C). The expression of 
mtDNA-encoded COl and NDI mRNAs was stimulated 48 to 72 h after E2 treatment 
(Figure 19B), and this increase was similarly inhibited by ICI 182,780 (Figure 19C). 
Together these data demonstrate that the E2-induced increase in NRF-l results in a 
downstream increase in its target gene TF AM and mtDNA-encoded Tfam target genes 
MTCOI and MTNDI in an ER-dependent manner in MCF-7 cells. 
To further examine the downstream effects ofE2-induced NRF-l upregulation, 
the expression of COl (mtDNA encoded) and COIV (nuclear encoded) proteins was 
evaluated (Figure 20A). These proteins are both subunits of Complex IV in the electron 
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Figure 18: NRF-l protein levels are increased by E2 treatment. A representative 
western blot is shown for NRF -1 expression in 10 nM E2-treated MCF -7 cells above a 
summary graph for NRF-l normalized to a-tubulin from the same blot. Values are the 
average of 3 separate experiments ± SEM. a = P< 0.05 compared to EtOH. 
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Figure 19: Secondary gene expression is increased in E2-treated MCF-7 cells. (A) 
MCF-7 cells were treated with EtOH or 10 nM E2 for the indicated times and QRT-PCR 
was performed for Tfam (A, black bars) or COl and NDI (B, white bars and C, grey 
bars). Where indicated, cells were pretreated with ICI 182,780 for 6 h (C). The total 
mRNA was isolated following treatment and QRT-PCR was performed as described in 
Material and Methods. Values are the average of 3-6 separate experiments ± SEM. 
a = P< 0.05 compared to EtOH. 
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EtOH 24 48 72 h 
Figure 20: Protein expression of secondary genes is increased in Ertreated MCF-7 
cells. A representative western blot of COl and COIV mRNA expression in 10 nM E2-
treated MCF-7 cells is shown above a summary graph of the data normalized to PDI in 
the same blots. Values are the average of 3 separate experiments ± SEM. 
a = P< 0.05 compared to EtOH. 
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transport chain. COl is transcriptionally regulated by Tfam and TFBs while COIV is a 
target ofNRF-1 (67). E2 induced a significant increase in both proteins after 48 and 72 h. 
Mitochondrial Biogenesis is Increased by E~ 
To determine ifthe previously described E2-induced increase in mRNA and 
protein levels in NRF -1 and its downstream targets lead to a subsequent induction in 
mitochondrial biogenesis, I measuring two endpoints of mitochondrial biogenesis: 
mtDNA copy number and 02 consumption. mtDNA copy number was assayed by semi-
quantitative PCR using primers that recognized a 250 bp region of the mtDNA 
normalized to primers for the 18S gene. E2 significantly increased mtDNA copy number 
after 24, 48, and 72 h (Figure 21). Because Tfam is essential for mtDNA replication (99), 
these data are consistent with the increase in E2-induced Tfam mRNA beginning at 12 h. 
O2 consumption was used as a measure of MRC function in E2-treated MCF-7 
cells. First, in preliminary experiments, I examined how serum starvation (IMEM with 
10% CCS-FBS for 4 d) followed by treatment with or without 0.1 % EtOH affected O2 
consumption. These experiments were completed to determine if EtOH or extended 
starvation had an effect on 02 consumption in the MCF -7 cells. This concentration of 
EtOH was chosen because it is the highest amount of total EtOH added to cell culture 
media as vehicle for the E2 treatment. I wanted to ensure that the EtOH itself was not 
affecting O2 consumption. Additionally, I compared the rate of 02 consumption in MCF-
7 cells in CCS-FBS-containing media to those for MCF-7 cells grown normal growth 
media consisting of 1M EM supplemented with 10% FBS. It was previously reported that 
treatment with serum devoid of steroids induced a shrinkage in mitochondria size and a 
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loss of well defined cristae, implying a decrease in mitochondrial activity, that was 
resolved by 4 d of culture in 10% FCS-containing media (117). Therefore, it is possible 
that placing the cells in CCS-FBS-containing media alone may affect their ability to 
consume 02. 
EtOH added to 10% CCS-FBS IMEM did not affect the rate of O2 consumption 
when compared to 10% CCS-FBS IMEM alone (Figure 22). However, growth in 10% 
CCS-FBS supplemented media did result in a decrease in 02 consumption when 
compared to the Growth Media. Clearly, the absence of hormones in the CCS-FBS 
media lead to a decrease in mitochondrial O2 consumption. This is consistent with 
previous reports indicating a lack of hormones in culture media or endogenous circulating 
E2 leads to impaired MRC activity (80,114,117). 
Subsequently, cells were treated with E2 for 2,4, or 6 days and 02 consumption 
measured. A significant increase in 02 consumption was seen after 4 and 6 d of E2 
treatment (Figure 23). This is consistent with the upregulation of COl and COIV proteins 
beginning at 48 h which, in concert with increased expression of MRC proteins resulting 
from NRF -1, Tfam, and TFB activity would lead to an increase in oxygen consumption in 
the cell. These data also agree with previous reports detailing a loss of respiratory chain 
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Figure 21: E2 increases mtDNA copy number. (A) MCF-7 cells were treated with 
EtOH or 10 nM E2 for the indicated times. A summary graph of 4 experiments 
evaluating mtDNA normalized to 18S expression by semi-quantitative PCR is shown 
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Figure 22: EtOH does not affect O2 consumption rates. O2 consumption was 
measured in MCF-7 cells grown in either 10% FBS containing IMEM (Growth Media), 
IMEM supplemented with 10% CCS-FBS (CCS-FBS Media), or IMEM containing 10% 
CCS-FBS and 0.1 % EtOH for 4 d. The average rate of 02 consumption from 3-4 
separate experiments is shown ± SEM in J.lg/mL. a = P< 0.05 compared to Growth 
Media. 
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Figure 23: E2 increases 02 consumption in MCF-7 cells. (A) 02 consumption was 
measured in MCF -7 cells treated with EtOH or 10 nM E2 for the indicated number of 
days and representative slopes are shown. (B) The average rate of 02 consumption from 
4-6 separate experiments is shown ± SEM in ug/mL. a = P< 0.05 compared to EtOH for 
the same time point 
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siRNA Knockdown ofNRF-l in MCF-7 Cells 
siRNA knockdown ofNRF-1 followed by E2 treatment was utilized in order to 
ensure that the E2-ER mediated positive effects on mitochondrial activity and gene 
expression were indeed controlled by NRF -1. MCF -7 cells were first transfected with 
siRNA targeting NRF-1 and WCE extracts were prepared and analyzed by Western Blot 
for NRF-1 protein expression. NRF-l protein expression was decreased by 50% 
compared to control siRNA (Figure 24). 
QRT-PCR was performed to examine secondary gene expression in parallel to 
experiments done in Figure 15. MCF-7 cells were transfected with Control siRNA or 
siRNA targeting NRF-1 and the expression of Tfam, COl, and NDI was examined in 
response to E2. Previously, all three genes were significantly up-regulated by E2 
treatment after 48 h. However, siRNA knockdown ofNRF-1 followed by treatment with 
E2 resulted in no increase in secondary gene expression. In these cells, Tfam, COl, and 
NDI were all significantly decreased in comparison to the nontransfected MCF-7 cell 
samples. Only, Tfam and NDI were significantly decreased compared to the Control 
siRNA (Figure 25). In addition to a lack of increased secondary gene mRNA, protein 
expression of two secondary genes was not increased by E2 in the NRF -1 knockdown 
MCF-7 cells. Previously, a significant increase in COl and COIV was observed after 48 
h of E2 treatment in MCF -7 cells (Figure 16). However, MCF -7 cells transfected with 
siRNA to NRF-l followed by E2 treatment did not respond with a rise in protein 
expression (Figure 26). 
Finally, in order to demonstrate that the ER mediated positive effects are directed 
through NRF -1, mtDNA copy number was measured in MCF -7 cells transfected with 
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siRNA targeting NRF-l. Previously, mtDNA was observed to be increased by E2-
treatment of MCF -7 cells at 48 h. It was assumed that the increase in mtDNA was due to 
an NRF-1 induced in crease in Tfam and other mitochondrial transcription factors. To 
test this hypothesis, MCF-7 cells were transfected with siRNA targeting NRF-1 and an 
increase in mtDNA was measured at 48h ofE2-treatment. siRNA knockdown ofNRF-1 
inhibited the increase in mtDNA observed in prior experiments (Figure 27). 
Overall, the results from the NRF -1 knockdown experiments indicate that the 
positive effects on mitochondrial gene expression through ER are being mediated by the 

























Figure 24: Transfection with siRNA targeting NRF-l decreases NRF-l protein 
expression. A representative western blot of MCF -7 cells transfected with Control 
siRNA or siRNA targeting NRF -1 is shown above a summary graph of the data 
normalized to a-tubulin in the same blots. Values are the average of 3 separate 

















siRNA to NRF-l 
Figure 25: Secondary gene expression is not increased in E2-treated MCF -7 cells 
transfected with siRNA targeting NRF-l. MCF-7 cells were not transfected or 
transfected with Control siRNA (treated with EtOH) or siRNA targeting NRF-l (treated 
with E2)' The cells were treated for 48 hand QRT-PCR was performed for Tfam, COl, 
and NDI. The total mRNA was isolated following treatment and QRT-PCR was 
performed as described in Material and Methods. Values are the average of3-6 separate 







siRNA to NRF-1 
Q) 
bJ) 




COIV "0 0.5 ~ 
a-tubulin (.'r. 
0 
Control siRNA to 
siRNA NRF-I 
Figure 26: Protein expression of secondary genes is not increased in Ertreated 
MCF-7 cells transfected with siRNA targeting NRF-l. MCF-7 cells were transfected 
with Control siRNA (treated with EtOH) or siRNA targeting NRF -1 (treated with E2). 
WCE were made from 48 hr treated samples as described in Materials and Methods. A 
representative western blot of COl and COIV protein expression is shown next to a 
summary graph of the data normalized to a-tubulin in the same blot. Values are the 
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Figure 27: The E2-induced increase in mtDNA copy number is inhibited in MCF-7 
cells transfected with siRNA targeting NRF-l. MCF-7 cells were transfected with 
Control siRNA (treated with EtOH) or siRNA targeting NRF-l (treated with E2). 
Genomic DNA was made from 48 hr treated samples as described in Materials and 
Methods. A summary graph of 3 experiments evaluating mtDNA normalized to 18S 
expression by semi-quantitative PCR is shown along with a representative agarose gel. 
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DISCUSSION 
While it is clear that estrogens have protective effects on mitochondrial function 
in multiple cells types, it is unclear how these effects are mediated. Several theories have 
been postulated regarding the action of ER on mitochondrial structure and function. The 
results of my research demonstrate that E2 directly activates a genomic mechanism of ER 
action that impacts mitochondrial function. E2 increases transcription ofNRF-l which is 
an established integrator of nuclear and mitochondrial interactions (67). The increase in 
NRF -1 mRNA and protein in response to E2 agrees with the report that NRF -1 protein 
was increased in the cerebral blood vessels ofE2-treated Ovx rats (114). These results 
may explain previously observed increases in mitochondrial activity in response to E2 
(106,108,109,114), but do not rule out a role for ER action within the mitochondria as 
postulated by other investigators (110,152). A role for nongenomic E2 action in 
mediating NRF -1 transcription is unlikely because inhibitors of the two predominant 
nongenomic signaling pathways in MCF-7 cells (153,154), MAP Kinase ,md PI3 Kinase, 
had no effect on E2-induced NRF-l expression. Likewise, E2 increased the transcription 
of genes regulated by NRF-l: TFAM, and subsequently, in a time-delayed manner, 
mtDNA-encoded Tfam-regulated COl and NDI mRNA. These data are in agreement 
with a report demonstrating a 2-fold increase in COl mRNA with E2 treatment in MCF-7 
cells (75); however, there was a time difference noted between that study and my results. 
I detected an increase in COl at 48 h whereas the previous report (75) indicated this 
increase at 12 and 24 h after E2-treatment ofMCF -7 cells. The use of a la-fold higher E2 
concentration (100 nM, non-physiologic) in the previous study may account for the 
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difference in induction times. 
Consequent to the increase in NRF-I and in secondary gene expression, including 
increased COl and COIV proteins, an increase in mtDNA and O2 consumption was 
observed. The increase in mtDNA in concert with COl and NDI suggests a pathway by 
which E2-induced NRF-I and a subsequent increased Tfam activates both transcription 
and mtDNA replication as detailed in Figure 28. In parallel, E2 increased O2 
consumption which is an index of MRC activity. Whether this increase is due to 
increased MRC activity or an increase in mitochondrial biogenesis leading to more 
mitochondria per cell remains to be determined. 
It is plausible that the secondary gene increases and increases in mitochondrial 
biogenesis are controlled by a yet undetermined protein and not NRF -I. siRNA studies 
targeting NRF -I were undertaken in order to further solidify the relationship between an 
E2-induced increased in NRF-I by ER leading to the positive effects on secondary 
mitochondrial gene expression and increases in mtDNA. These studies confirm that 
NRF-I is essential for mediating the downstream effects ofE2-ER (Figures 25-27). An 
increase in secondary gene expression, secondary gene protein production ,and mtDNA 
was absent when NRF-I was removed from the system despite the presence ofE2. 
In summary, my studies identified NRF-I as a primary estrogen target gene. The 
E2-stimulated increase in NRF -I was followed in a time-dependent manner by increases 
in NRF-I regulated Tfam mRNA and then, in tum, by Tfam-regulated COl and NDI 
mRNA expression. In concert with these changes in mRNA and protein expression, O2 
consumption and mtDNA copy number were increased by E2, indicating an increase in 
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mitochondrial biogenesis. Together these results suggest an important role for E2 in 
upregulating mitochondrial activity in estrogen-responsive cells. 
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Figure 28: A model of the regulation ofNRF-l by E2 and the subsequent 
downstream effects of this stimulation. (A) E2-occupied ER binds to the ERE in the 
NRF-l promoter leading to an increase in NRF-l promoter activity. (B) NRF-l 
subsequently increases the transcription of its nuclear-encoded target genes including 
Tfam and TFBs. (C) Tfam and TFBs are imported into the mitochondria where Tfam 
increases mtDNA replication and both Tfam and TFBs increase mtDNA transcription. 
(D) Resulting increases in the levels of MRC proteins leads to an increase in O2 
consumption through Complex IV. 
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CHAPTER III 
ANALYSIS OF THE NUCLEAR RESPIRATORY FACTOR-1 PROMOTER REGION 
AND CONTRIBUTION OF THE PUTATIVE ESTROGEN RESPONSE ELEMENT 
INTRODUCTION 
Expression ofNRF-1 has been shown to be increased by a variety of 
environmental stimuli and hormones. NRF -1 mRNA was induced by electrical 
stimulation in cardiomyocytes (155), exogenous addition of a creatine analogue (156), 
activation of AMP kinase (156), and stimulated following bouts of exercise in skeletal 
muscle (94). Thyroid hormone (T3) increases NRF-1 gene expression through a hormone 
responsive element in the NRF-1 promoter (157,158). While glucocorticoids and 
estrogens have both been suggested to playa critical role in mitochondrial upregulation 
and mitochondrial gene expression (76,159), no one has evaluated ifthese hormones 
directly regulate NRF -1 transcription. Interestingly, a recent study revealed that NRF-1 
protein expression was increased in cerebral blood vessels of Ovx rats chronically treated 
with E2 compared to Ovx control, suggesting that estrogen may regulate NRF-1 
transcription (114). 
The Gene2Promoter program (160) was used to analyze the NRF-1 gene. 
Gene2Promoter scans the starting region of a target gene for promoter motifs and predicts 
the region most likely to contain the promoter in that gene. Gene2Promoter predicted the 
NRF -1 promoter to be within the -600 bp region of the NRF -1 start site. Using 
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MatInsepctor (161), an extended -5000 bp region 5' of the NRF-l start site was examined 
for putative transcription factor binding sites. However, only one ERE was detected at 
-963 to -944 of the NRF -1 transcriptional start site. A brief diagram detailing the -1100 
bp region of the NRF -1 promoter is shown in Figure 29 listing some of the many putative 
transcription factor binding sites predicted by MatInspector. For the purposes ofthis 
Aim, I decided to expand my cloning efforts beyond the predicted -600 bp promoter 
region out to the putative NRF-l ERE at -963 to -944 bp. It was previously reported that 
a -1000 bp region of the hNRF -1 gene contained the promoter based on transient 
transfections in COS, HeLa, and L6 Cells (162). In order to determine the contribution 
and function of the putative ERE, several approaches were taken. First, the -1100 bp 
region was cloned and inserted into a pGL2-basic-Iuciferase vector. Subsequently 
deletions were generated to examine smaller fragments of the promoter that did not 
contain the ERE. Next, the ERE was eliminated from the -1100 pGL2-construct using 
site directed mutagenesis, and finally, the 200 bp region surrounding the putative ERE 
was cloned into a pGL3-promoter-luciferase vector. By cloning the 200 bp surrounding 
the ERE, I was able to examine the activity of the ERE separated from the rest of the 
promoter. In Figure 30, the pGL2-basic-Iucferase and pGL3-promoter-luciferase 
constructs tested in transient transfection assays are diagramed. 
The putative NRF-l ERE (5'-CGGGCAtggTGTCCT-3') differs from the 
palindromic consensus ERE (5'-AGGTCAgagTGACCT-3) by 2 bp changes in the 5' 
half-site and one bp change in the 3' half-site indicated in bold. These changes, while 
reducing the affinity of ER for the ERE, do not eliminate the site. In fact, all three of the 
changes in the ERE site in the NRF -1 promoter occur at nucleotide positions previously 
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identified as lower in importance to the binding of ERa (163). An adaptation of the 
original description detailing the importance of each position of the ERE is shown in 
Figure 31 along with the putative NRF-l ERE and the proposed bp changes that were 
used to eliminate the ERE site in site-direct mutagenesis experiments (42,163). 
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Figure 29: 5' promoter region of the hNRF -1 gene. The -1100- + 1 region of the 
hNRF-1 promoter was analyzed using MatInspector to identify transcription factor 
binding sites as indicated. Some of the less common sites shown include CDF-1 = Cell 
cycle-dependent element; CDE/CHR =Cell cycle gene homology region (CDE/CHR 
tandem elements regulate cell cycle dependent repression); EGR1 = early growth 
response 1; MyoD: Myogenic regulatory factor MyoD (myf3) 
EBox:Member ofb-zip family, induced by ER damage/stress, binds to the ERSE in 
association with NF-Y; TCF/LEF-l: involved in the Wnt signal transduction pathway. 
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Putative ERE +1 




Putative ERE 5'-CGGGCA tggTGTCCT-3' 
Mutated ERE 5'-CTGGCCtggAGTCCT-3' 




pGL3-pro-NRF -1-(" 1007--807) 
pGL2-NRF -1-(-11 OOMU1) 
Figure 30: Promoter deletion and ERE mutant constructs of the hNRF-l promoter. 
The diagram shows the structures of the pGL2-basic- and pGL3-promoter-luciferase 
expression vectors containing various lengths of 5' -flanking regions of the human NRF-1 
gene promoter and a construct in which the ERE was mutated. The ERE is underlined in 
the wt putative NRF -1 ERE. The nuc1eotides in bold are different from the consensus 
ERE and the nuc1eotides in italics iridicate mutations compared to the wt NRF -1 ERE in 
the mutated pGL2-NRF-1-C1100MUT) construct. 
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Consensus ERE (5'-3') 
A GGT CA T G G T G AcCT 
Putative NRF-1 ERE 
C GGG CA T G G T G TcCT -
Mutated NRF-1 ERE 
C@ !:!G CC T G G~ TeCT 
Figure 31: Comparison of the nucleotide sequence of consensus ERE with the 
putative NRF-l ERE and mutated NRF-l ERE. The height of the nucleotides is 
relative to importance for ERa binding. The color scheme and model are based on motif 
screening of ERE binding sites in Chromosomes 21 and 22 by Carroll et al (163). The 
importance of each bp has been review in detail by Klinge (42). Nucleotides in black are 
different from the consensus ERE. The nucleotides changed in the synthetic mutated 
NRF -1 ERE are circled. 
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MATERIALS AND METHODS 
Cloning of the NRF -1 Promoter 
Primers were designed to the -1100 bp region of the NRF -1 promoter using 
Primer3 and are listed in Table 3. The -1100 bp fragment ofhNRF-l (NM_00501l) was 
cloned from human genomic DNA (Roche) into the pCR-Blunt II-Topo vector 
(Invitrogen). After sequencing, restriction digestion (XhoI/SacI) was used to subclone 
the -1100 promoter fragment into the pGL2-basic-Iuciferase vector (Promega). Primers 
were then designed to clone two smaller fragments of the NRF-l promoter at 
approximately 300 bp intervals. The primers designed resulted in a -677 bp fragment 
and a -378 fragment (see Table 3). Primers were also designed to clone the 200 bp region 
surrounding the putative NRF-l ERE. The -677, -378, and 200 bp fragments were 
inserted into the pCR-Blunt 11-Topo vector, sequenced, and subsequently digested 
(XhoJISacl), and placed into either the pGL2-basic-Iuciferase plasmid or the pGL3-
promoter-Iuciferase plasmid. The plasmids are named after their corresponding 
fragments as noted in Figure 30. 
The pGL2-NRF-I-CllOO) mutant ERE (pGL2-NRF-I-ClI00MUT)) was 
generated using the QuickChange Mutagenesis Kit (Stratagene) according to the 
manufacturer's protocol using the primers listed in Table 3. The primers introduced 2 bp 
changes into the 5'-half site and 1 bp change in the 3'-half site abolishing the palindromic 
ERE as described in Figure 31. Presence of the correct mutation was confirmed by 
sequencmg. 
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Primer Name Primer Sequence 
NRF-I-II00 Forward 5' -GAGTCTCCTGACGACACTAA-3' 
NRF -1 -1100 Reverse 5' -GAAGTTCTACTCAGAGCGGC-3' 
NRF-l -677 Forward 5'- TATCTGCACAGCACGAGAC-3' 
NRF -1 -677 Reverse 5' - GAAGTTCT ACTCAGAGCGGC-3' 
NRF-l -378 Forward 5' -CGCCGCTTCTCCGGGGCGTC-3' 
NRF-l -378 Forward 5' - GAAGTTCTACTCAGAGCGGC-3' 
NRF-l -1007- -807 Forward 5'-GAGTCTCCTGACGACACTAA-3' 
NRF-I-I007- -807 Reverse 5' -T AACGGTGGAGACACACGAG-3' 
Mutant ERE Fonvard 5' -CCCCTCTGCCTGGCCTGGAGTCCTGTAAT -3' 
Mutant ERE Reverse 5' -GCCTCCCAAAGTGCTGGTATTACAGGA-3' 
Table 3: Primer Sequences for Cloning and Mutagenesis of the NRF-l Promoter 
Constructs 
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Dual Lucifer:ase Assays in MCF-7 and HEK-293 Cells with NRF-l Promoter 
Constructs 
MCF-7 cells were plated in 24-well plates at a density of lxl05 cells/well in 
growth media consisting ofIMEM with 10% FBS. HEK-293 cells were plated in 24-well 
plates at a density of lxl05 cells/well in growth media consisting of Alpha MEM 
(Invitrogen) with 10% FBS. After 24 h in growth media, the cells were placed in 10% 
CCS-FBS supplemented media and transfected. The MCF-7 cells were transfected with 
pGL2-NRF-I-C1100), pGL2-NRF-I-C1100MUT), pGL2-NRF-I-(677), pGL2-NRF-I-C 
378), pGL3-pro-NRF-I-C1007--807), pGL3-pro-luciferase, or pGL2-basic-luciferase 
parental vector using FuGene 6 at a 3:1 FuGene 6 to DNA ratio. Each well received 250 
ng of the luciferase reporter plasmid and 5 ng of a Renilla luciferase internal control 
reporter (pRL-tk) from Promega. Since HEK-293 cells are ER null, transient 
transfections in HEK-293 cells proceeded as described for the MCF-7 cells, however 
either 10 ng ofpCMV-ERu (provided by B.S. Katzenellenbogen) or pcDNA3.1-
ER~ (provided by lan-Ake Gustafsson) were also cotransfected with the reporter and 
Renilla vector. Twenty-four hours after transfection, triplicate wells were treated with 
EtOH (vehicle control), 10 nM E2, 100 nM ICI 182,780, or a combination ofICI 182,780 
and E2. The cells were harvested 30 h post-treatment using Promega's Passive Lysis 
buffer. Luciferase and Renilla luciferase activities were determined using Promega's 
Dual Luciferase assay in a Plate Chameleon Luminometer (BioScan) (32). Firefly 
luciferase was normalized by Renilla luciferase to correct for transfection efficiency. 
Fold induction was determined by dividing the averaged normalized values from each 
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treatment by the EtOH value for each transfection condition within that experiment. 
Values were averaged from multiple experiments as indicated in the Figure legends. 
Chromatin Immunoprecipitation Assays 
Chromatin Immunoprecipitation (ChIP) Assays followed methods previously 
described by Metiever et al. (164) and detailed in a flow chart in Figure 32. For the ChIP 
assays, MCF -7 cells were grown to 50% confluency in 150 mm plates and placed in 10% 
CCS-FBS supplemented IMEM media for 72 h prior to treatment. Approximately 4 x 
106 cells per immunoprecipitation (IP) were treated with 2.5 IlM a-amanitin for 2 h. The 
medium was then removed and replaced with media containing 10 nM E2 or EtOH for 60 
min. Chromatin-protein complexes were crosslinked by incubation with 1.5% 
formaldehyde for 5 min at 37°C, and the cells were collected after 2 washings with PBS 
in Collection Buffer (100 nM Tris [pH 9.4], 100 nM Dithiothreitol (DTT), and 1 X 
Protease Inhibitors (Roche)). The samples were then incubated on ice for 15 min and 
then at 30°C for 15 min. The cells were disrupted sequentially by vortexing and 5 min of 
centrifugation at 3000 x g at 4°C with 5 ml Buffer A (10 mM EDTA, 0.5 mM EGTA, 10 
mM HEPES [pH 6.5] and 0.25%Triton X-I00) and then 5 ml Buffer B (1 mM EDTA, 0.5 
mM EGT A, 10 mM HEPES [pH 6.5] and 200 mM NaCl). The cells were sonicated 15 
times for 10 s at a setting of 1 in a (Sonifier Cell Disruptor, Branson, Danbury, CT) in 
200 ullysis buffer [10 mM EDTA, 50 mM Tris-HCI [pH 8.0], 1 % SDS]. 20 ul of extract 
was removed and a final concentration of 200 mM NaCI was added to the sample which 
was then incubated overnight at 65°C to facilitate decrosslinking of the protein-DNA 
complexes. 5 ul was run on a 0.8% agarose gel to ensure that the sonication resulted in 
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fragments in the range of2-0.5 kb. The remainder of the sonicated sample was diluted 
2.5-fold in IP buffer (2 mM EDTA, 100 mM NaCl, 20 mM Tris-HCl [pH 8.1], and 
0.5% Triton X-I 00). The samples were precleared by a 2 h incubation with 30 uL Protein 
AlG beads containing salmon sperm DNA (Upstate). The samples were then incubated 
with either anti-ERa (HC-20) antibody, anti-ER~ antibody (H-150), or normal rabbit IgG 
(all from Santa Cruz) overnight. Antibody-protein-DNA complexes were collected by a 
2 h incubation with 50 uL Protein AlG beads. The beads were washed by incubation 
with agitation for 10 min per wash with the following buffers: Low Salt Buffer (2 mM 
EDTA, 20 mM Tris-HCl [pH 8.0], 0.1 % SDS, 1 % Triton X-I 00, 150 mM NaCl ), High 
Salt Buffer (2 mM EDTA, 20 mM Tris-HCl [pH 8.0],1% Triton X-100, 500 mM NaCl), 
LiCl Buffer (1 mM EDTA, 10 mM Tris-HCl [pH 8.0],1% NP-40, 1% Deoxycholate, 
0.25 M LiCl), and TE (10 mM Tris, pH 8.0, 1mM EDTA). Immune complexes were 
eluted by incubation with Elution Buffer (l % SDS with 0.1 M NaHC03) for 30 min with 
vortexing every 5 min. A final concentration of 200 mM NaCl was added to the eluted 
fraction and the samples were incubated overnight at 65°C. The DNA was purified using 
the Qiagen PCR Clean-Up Kit (Qiagen), and probed for target sequences. Each PCR 
reaction included IX Green GoTaq Flexi Buffer, 1.5 mM MgCb, 0.2 mM of each dNTP, 
1 ~M reverse primer, 1 ~M forward primer, 1.25 units GoTaq, 3-7 ul eluted DNA, and 
nuclease free water to a total volume of20 uL. Primers for the putative NRF-1 ERE 
probed the -761 to -1032 bp region (see Table 4). As a positive control, primers flanking 
the established ERE in the human pS2 (Trefoil Factor 1; TFFI) gene promoter were used 
(164). As a negative control, primers were designed to a distal region (-3060 to -3208) of 
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the NRF-l promoter (see Table 4). PCR products were resolved on 2% agarose gels and 
stained with ethidium bromide. 
ERa and ERB Proteins 
Recombinant human ERa (165) and recombinant human ER~l (166) were 
expressed by baculovirus infection of Sf21 cells and were used for electrophoretic 
mobility shift assay (EMSA). The concentration of ERa and ER~ was determined by 
specific eH]E2 binding in a hydroxyapatite assay (167) and was 150 fmol//-1g dimer 
concentration for ERa and 95 fmol//-1g dimer concentration for ER~ 1. 
EMSA and ER-NRF-I-ERE KLDetermination 
The DNA oligonucleotide sequences used in EMSA were as follows: putative 
NRF-I-ERE from the human NRF-l promoter 5'-GGAAGCCGGGCATGGTGTCCTGT 
-3' a consensus ERE, i.e., EREc38 (5'-AGGTCACAGTGACCT-3') (168). EMSA was 
performed as previously described (58). In brief, oligomers were fill-in labeled with 
e2P]a-dTTP (NEN) using the Klenow fragment of E. coli Pol. I. as previously described 
(169). Baculovirus-expressed ERa and ER~ (41) were preincubated with E2 for Ih at 4° 
C prior to addition of the e2p]EREc38. All reactions used a fixed concentration of 
ERa (1.2 nM) or ER~ (1.5 nM) and included 60 mM KCI, 0.75 mg/~.tl purified BSA 
(New England Biolabs); 25 /-1g/ml poly(dI-dC) (Sigma); and 15% (v/v) glycerol in a final 
volume of20 /-11. The ER-e2 P]ERE-ER reaction was incubated for 30 min at room 
temperature prior to separation on 4% non-denaturing polyacrylamide gels (169). Dried 
EMSA gels were analyzed using a Packard Instruments Instant Imager and associated 
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MCF-7 placed in 10% Run 5 ul on a 0.8% t 
CSS-FBS for 72 h gel to confirm 
• sonication lengths Clean up DNA using t Quiagen Kit t 2.5 uM a-amanitin 
added for 2 h Clean up DNA using 
• Quiagen Kit Decrosslink t overnight t Cells washed and Decrosslink 20 ul for use 
treated with E2 or 
as Input and to confirm Elute with vortexing EtOH for 60 min 
fragment lengths in Elution Buffer • t t Dilute 2.5 fold in Chromatin Crosslinked 
for I h with 1.5% 
Sonicate 15 times for ... Dilution Buffer I Wash 2X with TE I 
formaldehyde 
10 s 
t • t • Preclear with Protein Pellet cells, resuspend Wash with LiCI Cells harvested in 
in Lysis Buffer 
AlG beads for 2 h Buffer 
Collection Buffer • t t • Remove beads and IS min incubation Pellet cells, resuspend incubate with Antibody Wash with High 
on ice. in Buffer B and vortex overnight 
Salt Buffer 
• t • t IS min incubation at Pellet cells, resuspend Remove beads and Wash with Low 
37°C ... in Buffer A and vortex incubate with Antibody ... Salt Buffer 
overnight 
Figure 32: Flow Chart Describing the ChIP Method. ChIP experiments proceeded as 
detailed above and in Materials and Methods. 
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Primer Name Primer Seguence 
NRF -1 ChIP Forward 5'- GGTCCCAGGACTCAAAACAA-3' 
NRF -1 ChIP Reverse 5'- CAGGTGCCTGAGAAGTAGGG-3' 
pS2 ChIP Forward 5'- GGCCATCTCTCACTATGAATCACTTCTGC-3' 
pS2 ChIP Reverse 5'-GGCAGGCTCTGTTTGCTTAAAGAGCG-3 ' 
NRF -1 Distal ChIP Forward 5'-ACCCTTGTGGAAACAGCATC-3' 
NRF -1 Distal ChIP Reverse 5'-AAACGGACTGGGCTTACCTT -3' 
Table 4: Primers Used for ChIP Experiments 
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software, Packard Imager for Windows v2.04 (16). 
To measure Ki in competition assays, reactions included 1.2 nM ERa or 1.5 nM 
ER~, 1.1 nM e2p]EREc38 (5'-
CCAGGTCAGAGTGACCTGAGCTAAAATAACACATT-3') (168), 100 nM E2, and 
0.5 nM - 20,000 nM unlabeled NRF-l- ERE (169). The concentrations of free and ER-
bound e2p]EREc38 were fitted to the one-site binding model (determination coefficient 
R2> 0.93 and 0.98 for ERa and ER~ with no ligand, 0.97 and 0.94 with E2). The value 
of the ICso was determined by equation of the Pseudo-Hill plot: log %/(100-%)=nlog{[I] 
+ nlogICso, where %= percent competition of specific binding, I=competitor (Figure 32B, 
left panel). The Ki was calculated from the ICso, using the equation of Cheng and Prusoff 
(170): Ki =ICso/(1 +[radioligand]/Kd). 
Statistics 
All statistical analyses were performed as described in Chapter II. 
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RESULTS 
Luciferase Reporter Assays with E~ and leI 182,780 
MCF-7 cells were first transfected with the NRF-l promoter constructs and 
parental vectors and the basal activity examined (Figure 33). The pGL2-NRF-I-(378), 
pGL2-NRF-I-(677), pGL2-NRF-I-ClI00), and pGL2-NRF-I-Cll OOMUT) all displayed 
a -20-fold increase in activity compared to the parental vector, pGL2-basic-Iuciferase 
which contains no promoter elements controlling the luciferase gene (Figure 33A). This 
increase in activity confirms the presence of a promoter region within all of the 
constructs. The pGL3-pro-Iuciferase parental vector and the pGL3-NRF-I-Cl007--807) 
displayed equivalent activity (Figure 33B). This activity level is much higher when 
compared to the activity levels seen in the pGL2 constructs due to the presence of a 
strong SV 40 promoter in the pGL3-pro-luciferase vector. This vector is designed to test 
putative enhancer sequences placed in front of the SV 40 driven luciferase gene. 
The effects of E2 on promoter function were first assayed by transient transfection in 
MCF-7 cells (Figure 34). E2 stimulated an increase in luciferase activity from the pGL2-
NRF-I-ClI00) construct which contains the putative ERE but not the pGL2-NRF-l- C 
677) or (378) constructs lacking the ERE. Treatment with ICI 182,780 had no effect on 
luciferase activity from the full length promoter construct (Figure 34); however, 
cotreatment of cells with E2 and ICI 182,780 ablated the E2-induced increase in luciferase 
activity. Transfection of the pGL3-pro-NRF-I-Cl007--807) construct yielded an increase 
in luciferase activity in the presence of E2 that was blocked by cotreatment with ICI 
187,780 (Figure 35). This response was smaller than that seen in the full length promoter 
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construct. These data indicate that the region from -1007 to -807 containing the putative 
ERE is estrogen-responsive. 
Mutagenesis was performed to eliminate the putative ERE from the pGL2-NRF-
l-C1100) construct to further evaluate the role ofthe putative ERE in the estrogen 
response. As demonstrated in Figure 34B, when nucleotides within the core ERE were 
mutated within the pGL2-NRF-I-C1100) construct, E2 did not stimulate luciferase 
activation. These results indicate that the E2-induced reporter activity is mediated by ER 
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Figure 33: Activity of the NRF-l promoter constructs in MCF-7 cells. (A) MCF-7 
cells were transfected with the indicated parental or pGL2-NRF-l promoter constructs 
and luciferase and Renilla values measured as described in Materials and Methods. (B) 
MCF-7 cells were transfected with the indicated pGL2-basic-luciferase or pGL3-pro-
luciferase parental vector or with the pGL3-NRF-l ClO07 - -807) construct. The cells 
were harvested 48 h post-transfection, WCE were prepared and dualluciferase assays 
were performed as described in Materials and Methods, Values are relative luciferase 
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Figure 34: Effect ofE2 on luciferase activity from NRF-l promoter constructs in 
transiently transfected MCF -7 cells. MCF-7 cells were transfected with the indicated 
pGL2-NRF-1 promoter constructs and Renilla luciferase. Twenty-four h post-transfection 
the cells were treated with EtOH, 10 nM E2, 100 nM ICI 182,780, or 100 nM ICI 182,780 
plus 10 nM E2 for 30 h as described in Materials and Methods. 30 h after treatment, 
WCE were prepared and dualluciferase assays were performed as described in Materials 
and Methods. Values are luciferasel Renilla luciferase activity normalized to the EtOH 
control for each construct. Values are the mean ± SEM of 4. a = P< 0.05 compared to 
EtOH; b=P<0.05 compared to E2 
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Figure 35: Effect ofE2 on luciferase activity from pGL3-pro-NRF-1-Cl007--S07) in 
transiently transfected MCF-7 cells. MCF-7 cells were transfected with pGL3-pro-
luciferase or pGL3-pro-NRF-1-Cl007--807) and Renilla luciferase. 24 h post-
transfection, the cells were treated with EtOH, 10 nM E2, 100 nM ICI 182,780, or 100 
nM ICI 182,780 plus 10 nM E2 for 30 h. WCE were prepared and dualluciferase assays 
were performed as described in Materials and Methods. Values are luciferasel Renilla 
luciferase activity normalized to the EtOH control for each construct. Values are the 
mean ± SEM of 3 experiments. a = P< 0.05 compared to EtOH; b=P<0.05 compared to 
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Transient transfections with the pGL2-basic-Iuciferase constructs were 
subsequently repeated in HEK-293 ER-null cells with either ERa or ER~ cotransfected 
as described in Materials and Methods. These transfections allow the contribution of 
each ER subtype to the luciferase induction to be further examined. Prior to 
cotransfection with ERa or ER~, the basal activity of the NRF-1 promoter constructs 
were examined in HEK-293 cells (Figure 36A). As seen in the MCF-7 control 
experiment (Figure 33A), the pGL2-NRF-1 constructs demonstrate an increase in basal 
luciferase activity compared to the parental vector (pGL2-basic-Iuciferase) indicating the 
presence of a promoter within the constructs. In contrast to the MCF-7 results, in which 
equal activity was seen between the pGL2-NRF-1-(378), pGL2-NRF-1-(677), pGL2-
NRF-1-Cl100), and pGL2-NRF-1-Cl100MUT) plasmids, the HEK-293 cells demonstrate 
an increasing amount of activity with increasing length of the promoter. These 
differences are likely a cell-specific difference in the expression of transcription factors 
and coregulators (171-173). When pGL2-NRF-1-Cl100) transfected HEK-293 cells were 
treated with E2 in the absence of transfected ER, no increase in relative luciferase activity 
was seen (Figure 36A). In parallel with the MCF-7 control transfections, pGL3-pro-
luciferase and pGL3-pro-NRF-1-Cl007--807) were transfected into HEK-293 cells in the 
absence ofER (Figure 36B). Both plasmids had equivalent basal activity in HEK-293 
cells, and treatment ofpGL3-pro-NRF-1-ClO07--807) with E2 did not result in an 
increase in luciferase activity. 
In the presence of cotransfected ERa, E2 stimulated an increase in luciferase 
activity from the pGL2-NRF-1-CllOO) plasmid construct which contains the putative 
ERE but not the pGL2-NRF-l- (677), (378), or ClIOOMUT) constructs lacking the 
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ERE (Figure 37 A and B). Cotreatment of cells with E2 and ICI 182,780 ablated the E2-
induced increase in luciferase activity. This agrees with data from the MCF-7 
transfections. However, E2 did not stimulate a significant increase in any of the 
constructs in the presence ofERP (Figure 37C and D). When pGL3-pro-NRF-1-ClO07--
807) was transfected in the presence of ERa or ERP, a significant increase in luciferase 
activity was seen in the presence ofE2 (Figure 38A and B). The increase seen in the ERa 
transfected cells was greater than the increase observed in ERP cotransfected HEK-293 
cells, 1.8- and 1.3-fold, respectively. The increase in E2 was ablated by cotreatment with 
ICI 182,780, further indicating the ER specificity of the induction (Figure 38A and B). 
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Figure 36: Basal activity of the NRF -1 promoter constructs in HEK-293 cells. (A) 
HEK-293 cells were transfected with the indicated parental or pGL2-NRF-l promoter 
constructs and Renilla luciferase and treated with EtOH or 10 nM E2 24 h post-
transfection. (B) HEK-293 cells were transfected with the indicated parental vector or 
pGL3-NRF-l construct and treated with EtOH or 10 nM E2 24 h post-transfection. WeE 
were prepared 30 h after treatment and dualluciferase assays were performed as 
described in Materials and Methods. Values are relative luciferase units (RLU)/ Renilla. 
Values are the mean ± SEM of 3 experiments. 
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Figure 37: Effect ofE2 on luciferase activity from NRF-l promoter constructs in 
transiently transfected HEK-293 cells. (A) and (B) HEK-239 cells were transfected 
with the indicated pGL2-NRF-1 promoter constructs, ERa, Renilla luciferase, and treated 
with EtOH, 10 nM E2, 100 nM leI 182,780, or 100 nM leI 182,780 plus 10 nM E2 for 24 
h as described in Materials and Methods. (C) and (D) HEK-239 cells were transfected 
and treated as listed for (A) and (B) with the exception that ER~ was transfected in place 
of ERa. WeE were prepared 30 h after treatment and dualluciferase assays were 
performed as described in Materials and Methods. Values are luciferasel Renilla 
luciferase activity normalized to the EtOH control for each construct. Values are the 
mean ± SEM of 4. a = P< 0.05 compared to EtOH; b=P<O.05 compared to E2 
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Figure 38: Effect ofE2 on luciferase activity from pGL3-pro-NRF-1-ClO07--807) in 
transient transfections in HEK-293 cells. (A) HEK-293 cells were transfected with 
ERa, Renilla luciferase, and either pGL3-pro-luciferase or pGL3-pro-NRF-1-ClO07--
807). The cells were treated with EtOH, 10 nM E2, 100 nM leI 182,780, or 100 nM leI 
182,780 plus 10 nM E2 24 h post-transfection. (B) HEK-239 cells were transfected and 
treated as listed for (A) with the exception that ER~ was transfected in place of ERa. 
weE were prepared 30 h after treatment and dualluciferase assays were performed as 
described in Materials and Methods. Values are luciferasel Renilla luciferase activity 
normalized to the EtOH control for each construct. Values are the mean ± SEM of 3 
experiments. a = P< 0.05 compared to EtOH; b=P<0.05 compared to E2 
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ER Binds to the Putative NRF -1 ERE in vivo and in vitro 
ChIP assays were used to evaluate whether ERa and ERP bind directly to the putative 
ERE (-944 to -963) in the NRF-l promoter. The location of the NRF-l ChIP primers is 
shown in Figure 39A. pS2 is an E2-responsive gene that contains a well characterized ERE 
which has been shown to recruit both ERa and ERP in the presence ofE2 in MCF-7 cells 
(174), hence serving as a positive control. A distal region of the NRF-l promoter (-3060 to-
3208) was used as a negative control. I observed that both ERa and ERP are present on the 
putative NRF -1 and pS2 EREs in MCF -7 cells after E2 treatment (Figure 39B). No binding 
of ERa or ERP was indicated in the negative control in the presence or absence of E2. 
EMSA performed by Dr. Margarita M. Ivanova indicated that ERa and ERP bind 
directly to the putative ERE in the NRF-l promoter without ligand and in the presence of 
E2 and 4-0HT (Figure 40). 
Deviation from the perfect consensus ERE correlates with decreasing affinity of 
ER-ERE binding (42). To determine the Ki of the ER-NRF-I-ERE interaction, 
competition EMSAs were performed (Figure 41). As shown, the NRF-I-ERE had 
~1,OOO-fold lower binding affinity for ER than EREc38. The binding affinity was similar 
for unliganded ERa and ERP with a Ki = 668 ± 76.2 nM and 699±71 nM, respectively 
and 1056 ± 98 nM and 895± 51 nM for E2-ERa and for E2-ERP, respectively. 
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Putative NRF-l ERE 
5'-CGGGCA tggTGTCCT-3' cf> 
-963 to -944 
~------~V~-----~,..r~--------~~ 
---. +- -. +-









Figure 39: ERa and ER~ bind to the putative NRF-l ERE in vivo. (A) A diagram of 
the NRF-l promoter and putative ERE (-963 to -944) with the location of the ChIP 
primers shown. ERE half-sites are underlined and letters in bold indicate deviations from 
the consensus ERE. (B) MCF-7 cells were treated with EtOH or E2 for 1 h and ChIP was 
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Figure 40: ERa and ER~ bind to the putative NRF-l ERE in vitro. Baculovirus-
expressed ERa and ER~ were incubated with e2P]-labeled NRF-l ERE in the presence 
ofE2, 4-0HT, or no ligand, as indicated. EMSA was perfonned as described in Materials 
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Figure 41: ERa and ER~ bind the NRF-l ERE with reduced affinity in comparison 
to a palindromic ERE. (A) Competitive EMSAs were performed using unliganded 
(top) or E2-liganded ERa (left) and ER~ (right) incubated with 1.1 nM e2PJEREc38 plus 
increasing concentrations of non labeled NRF-1-ERE as indicated and described in 
Materials and Methods. ERa and ER~ antibodies G20 and N19, respectively, were 
included in the indicated binding reactions to demonstrate the specificity of the bound 
complex (SS). (B) Competitive binding curves are shown for ERa (open boxes) and 




Results of previous experiments (Chapter I, Figure 12A) suggested that both 
subtypes of ER could contribute to the E2-stimulated increase in NRF -I mRNA 
transcription. Transient transfections in MCF-7 cells revealed that endogenous ER could 
induce activity in constructs containing the NRF-I ERE. Using HEK-293 cells, the 
contribution of ERa and ER~ were examined. Cotransfection with ERa and the full 
length pGL2-NRF-I-CI 100) promoter construct in the presence ofE2 resulted in a 
significant increase in luciferase activity; however, this effect was not seen when ER~ 
was cotransfected with pGL2-NRF-I-CI 100). In a similar manner, cotransfection of 
ERa or ER~ with pGL3-pro-NRF-I-CI007--807) resulted in a significant increase in 
luciferase activity. This increase was greater in HEK-293 cells cotransfected with ERa 
than ER~: 1.8- and 1.3-fold, respectively. The differences in fold induction are likely due 
to the different transcriptional activities of the two ER subtypes. ERa is known to be a 
more potent inducer of reporter activity while ER~ is a weaker inducer of reporter 
activity (58). Overall, the results of the transient transfection assays utilizing promoter 
deletion analysis and site-directed mutagenesis revealed that the ERE in the promoter of 
the NRF-l gene is capable of mediating the E2-induced increase in luciferase activity 
observed in the full length pGL2-NRF-I-CI 100) construct. 
In order to examine the direct interaction of ER with the NRF -I ERE, both in vivo 
and in vitro methods were used. EMSA experiments revealed direct binding of ERa and 
ER~ to the NRF-l ERE in vitro. However, the affinity of this interaction measured in 
EMSA experiments was low. Despite the low affinity of ERa and ER~ binding to the 
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NRF-l ERE, in vivo ChIP assays revealed that the putative NRF-l ERE is occupied by 
both ERa and ERP in response to E2, similar to the pS2 promoter, an established ER 
target gene (164). This suggests that genomic ERa and ERP bind to the NRF-I ERE in 
response to E2 in MCF -7 cells in vivo. 
Inclusively, the experiments presented in this chapter demonstrate that I have 
identified an ERE in the promoter of the NRF -1 gene that binds ERa and ERP in vivo 
and with low affinity in vitro. This adds NRF -1 to the list of genes regulated by non-
palindromic, low affinity ER-ERE binding. 
104 
CHAPTER IV 
REGULATION OF NUCLEAR RESPIRATORY FACTOR-1 IN MCF-7 AND H1793 
CELLS BY 4-HYDROXYTAMOXIFEN AND RALOXIFENE 
INTRODUCTION 
As previously discussed, SERMs have the ability to act as agonists in a cell-type 
and gene-type specific manner. Many researchers have evaluated the gene induction 
patterns in cells and tissues in response to E2; however, relatively little experimental work 
has been done in to identify genes uniquely up-regulated by TAM and RAL, two of the 
mostly commonly used clinical SERMs. One study has been published that specifically 
looked at unique gene regulation by ER subtypes in combination with TAM and RAL. 
Studies in U20S osteosarcoma cells stably expressing either ERa or ERP demonstrated 
that very few of the genes identified as upregulated by ERa or ERP individually were 
regulated by both ERa and ERP (27% of the total ERa and ERP upregulated genes) in 
TAM- and RAL- treated cells (175). This suggests that each subtype ofER regulates a 
unique set of genes in response to SERMs (175). In agreement with the previous set of 
data, an additional study examining the effect of co-expression of both ER subtypes in 
U20S cells showed that TAM regulated 27% of the total amount of up regulated genes 
observed exclusively through the presence of both subtypes (176). This suggests a 
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unique gene expression pattern regulated by heterodimers of ERa/ERp compared to 
either individual subtype (176). The possibility that heterodimers could uniquely regulate 
a subset of genes can complicate the interpretation of existing data. 
MCF -7 cells were classically considered to be ERa positive and ERP negative. 
Recently, this was found not to be true of all MCF-7 cells (147). In our own lab, MCF-7 
cells express equivalent amounts of ERa and ERP protein (32). This means that 
conclusions drawn from micro array studies in different labs that did not comment on the 
receptor status of their MCF-7 cell line may result in variation in the data. This may be 
speculative, but it demonstrates the difficulty in not only looking at the sparse amount of 
existing data on TAM and RAL gene regulation but in designing studies to more clearly 
examine these interactions. 
In the following set of experiments, I examined the effect of 4-0HT and RAL on 
the expression ofNRF-l. Originally, I used 4-0HT treatment ofMCF-7 cells as a 
negative control, expecting no effect on basal NRF-I transcription and that 4-0HT would 
inhibit E2-induced NRF-I expression, i.e., have antagonist activity similar to ICI 182,780. 
However, 4-0HT did not act in the expected manner. Thus, the following set of 
experiments was undertaken to determine the mechanism by which 4-0HT induced NRF-
1 transcription. In addition to 4-0HT, a second clinically used SERM, RAL was also 
used since it has lower agonist activity than 4-0HT (52). 
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MATERIALS AND METHODS 
RNA Isolation, RT -PCR and QRT -PCR 
All RNA Isolations, RT-PCR, and QRT-PCR were performed as described in 
Chapter II. 
Transient Transfection and Dual Luciferase Assays in MCF -7 and HEK-293 Cells 
with NRF -1 Promoter Constructs 
All transient transfections and luciferase assays were performed as described in 
Chapter III. 
Chromatin Immunoprecipitation Assay 
All ChIP assays were performed as described in Chapter III 
Statistics 
All statistical analyses were performed as described in Chapter II. 
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RESULTS 
4-0HT and RAL Increase NRF-l mRNA in a Concentration- and Time-
Dependent Manner in MCF -7 and H1793 Cells 
Both MCF-7 and H1793 cells were treated with increasing concentrations, i.e., 10 
nM-1 11M, of either 4-0HT or RAL. Both 4-0HT and RAL increased NRF-1 mRNA in a 
concentration-dependent manner in MCF-7 cells (Figure 42A and C). A significant 
increase was seen beginning at 100 nM for both SERMs in MCF-7 cells. H1793 cells 
also demonstrated an increase in NRF -1 mRNA in a concentration-dependent manner 
with maximum induction occurring at 100 nM 4-0HT and RAL (Figure 43A and C). A 
time course using the 100 nM concentration was then performed for both 4-0HT and 
RAL in MCF-7 and H1793 cells. In MCF-7 cells, 4-0HT displayed a time-dependent 
increase in NRF-1 mRNA beginning at 1 h, peaking at 4 h, and ending by the 12 h time 
point (Figure 42B). H1793 cells displayed a time-dependent 4-0HT-mediated rise in 
NRF-1 mRNA starting at 2 h, culminating at 4 h, and ending by the 12 h time point 
(Figure 43B). In MCF-7 cells, RAL did not increase NRF-1 mRNA levels until 2 h post-
treatment and the induction ended by the 8 h time point (Figure 42D). H1793 cells 
displayed an earlier RAL-stimulated increase in NRF-1 mRNA beginning at 1h, peaking 
at 4 h, and ending by the 8 h time point (Figure 43D). 
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Figure 42: 4-0HT and RAL increase NRF-l mRNA in a concentration- and time-
dependent manner in MCF-7 cells. MCF-7 cells were treated with increasing amounts 
of 4-0HT (A) or RAL (C). MCF-7 cells were treated for the indicated times with 100 
nM 4-0HT (B) or 100 nM RAL (D). The total mRNA was isolated and QRT-PCR was 
performed as described in Material and Methods. Values are the average of 3-6 separate 
experiments ± SEM. a = P< 0.05 compared to EtOH 
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Figure 43: 4-0HT and RAL increase NRF-l mRNA in a concentration- and time-
dependent manner in H1793 cells. H 1793 cells were treated with increasing amounts 
of 4-0HT (A) or RAL(C). H1793 cells were treated for the indicated times with 100 nM 
4-0HT (B) or 100 nM RAL (D). The total mRNA was isolated and QRT-PCR was 
performed as described in Material and Methods. Values are the average of3-6 separate 
experiments ± SEM. a = P< 0.05 compared to EtOH 
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Both 4-0HT and RAL have been shown to act through both genomic and 
nongenomic mechanisms (177-180). MCF-7 cells were treated with 4-0HT or RAL plus 
ICI 182,780 to first determine if the observed 4-0HT- and RAL- induced increases in 
NRF-1 mRNA were mediated by ER. Pretreatment with ICI 182,780 followed by 
treatment with ICI 182,780 plus 4-0HT or RAL decreased NRF-1 transcription compared 
to either 4-0HT or RAL alone (Figure 44A and B). This indicates that ER is involved in 
mediating the observed stimulation in NRF-l mRNA. To determine if the 4-0HT- and 
RAL- induced increase in NRF-1 mRNA are mediated by nongenomic ER activity, 
MCF-7 cells were pretreated for 1 h with the PI3 Kinase and MAP Kinase inhibitors 
Wortmannin and PD98059, respectively. Treatment with PD98059 did not significantly 
decrease the NRF-1 induction compared to 4-0HT or RAL alone indicating that the MAP 
Kinase pathway is not involved in mediating the NRF -1 induction by these SERMs 
(Figure 44A and B). However, treatment with Wortmannin inhibited both the 4-0HT-
and RAL- induced increase in NRF-l (Figure 44A and B). This data indicates 
involvement of the PI3 Kinase pathway in induction ofNRF-l transcription in response 
to either 4-0HT or RAL in MCF-7 cells. 
As show in Figure 43, NRF-1 mRNA increased in response to 4-0HT and RAL in 
H1793 cells as it did in MCF-7 cells (Figure 42). The effect of using Wortmannin and 
PD98059 in concert with 4-0HT and RAL was also tested in H1793 cells. In parallel to 
the results in MCF-7 cells, the 4-0HT induction ofNRF-1 mRNA is inhibited by both 
ICI 182,780 and Wortmannin (Figure 45A). This indicates a role for nongenomic 
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Figure 44: 4-0HT- and RAL- induced NRF-l transcription is mediated by 
nongenomic ER in MCF-7 cells. (A) MCF-7 cells were pre-treated with 50)lM 
PD98059 (PD) or 50 nM Wortmannin (Wort) for 1 h prior to incubation with 100 nM 4-
OHT for 4 h. (B) MCF-7 cells were pre-treated with PD or Wort for 1 h prior to 
incubation with 100 nM RAL for 4 h. The total mRNA was isolated following treatment 
and QRT-PCR was performed as described in Material and Methods. Values are the 
average of 3 separate experiments ± SEM. a = P< 0.05 compared to EtOH; b = P< 0.05 
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Figure 45: 4-0HT- and RAL- induced NRF-l transcription is mediated by 
nongenomic ER action in H1793 cells. (A) H1793 cells were pre-treated with 50 /lM 
PD98059 (PD) or 50 nM Wortmannin (Wort) for 1 h prior to incubation with 100 nM 4-
OHT for 4 h. (B) H1793 cells were pre-treated with PD or Wort for 1 h prior to 
incubation with 100 nM RAL for 4 h. The total mRNA was isolated following treatment 
and QRT-PCR was performed as described in Material and Methods. Values are the 
average of 3 separate experiments ± SEM. a = P< 0.05 compared to EtOH; b = P< 0.05 
compared to 4-0HT; c = P< 0.05 compared to RAL 
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PD98059 with RAL only partially blocked the RAL induced increase in NRF-l mRNA 
levels (Figure 45B). Wortmannin inhibited the RAL stimulated induction ofNRF-l 
(Figure 45B). 
These data indicate a role for nongenomic signaling through the PI3 Kinase 
pathway in mediating the 4-0HT and RAL induction ofNRF-l in MCF-7 cells. In 
H1793 cells, 4-0HT parallels the results in MCF-7. In these cells 4-0HT is signaling 
through the PI3 Kinase pathway. However, RAL appears to be acting through the PI3 
Kinase and MAP Kinase nongenomic pathways in H1793 cells. 
Dual Luciferase Assays in MCF-7 and HEK-293 Cells with NRF-l Promoter 
Constructs in the Presence of SERMs 
To further examine the agonist activity of 4-0HT and RAL on the NRF-l 
promoter, MCF-7 cells were transfected with each of the NRF-l promoter constructs and 
treated with 4-0HT or RAL (Figure 46A and 47A). The NRF-l promoter constructs 
were also transfected into HEK-293 cells cotransfected with either ERa (Figure 46B and 
47B) or ER~ (Figure 46C and 47C). In the MCF-7, HEK-293-ERa, and HEK-
ER~ transfections, 4-0HT and RAL did not have an effect on the reporter activity of the 
non-ERE containing reporters, pGL2-basic, pGL2-NRF-I-(378), pGL2-NRF-I-(677), or 
pGL2-NRF-I-C1100MUT) (Figure 46 and 47). The pGL2-NRF-I-C1100) and pGL3-
NRF -l-C 1007 --807) constructs containing the ERE sequence showed increased luciferase 
activity in response to 4-0HT and RAL in MCF-7, HEK-293-ERa and HEK-293-
ER~ transfections that was inhibited by ICI 182,780 (Figures 47 and 48). Notably, this 
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Figure 46: Effect of SERMs on luciferase activity from non-ERE containing NRF-l 
promoter constructs. MeF-7 (A), HEK-293-ERa (B), and HEK-239-ERP (e) cells 
were transfected with the indicated pGL2-NRF-l promoter constructs and Renilla 
luciferase. Twenty-four h later, the cells were treated with EtOH, 100 nM 4-0HT, or 100 
nM RAL. WeE were prepared 30 h after treatment and dualluciferase assays were 
performed as described in Materials and Methods. Values are luciferasel Renilla 
luciferase activity normalized to the ETOH control for each construct. Values are the 
mean ± SEM of 4. a = P< 0.05 compared to EtOH 
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Figure 47: Effect of SERMs on luciferase activity from ERE-containing NRF-l 
promoter constructs. MeF-7 (A), HEK-293-ERa (B), and HEK-239-ERP (e) cells 
were transfected with the indicated pGL2-NRF-l promoter constructs. Twenty-four h 
later, the cells were treated with EtOH, 100 nM 4-0HT, or 100 nM RAL. WeE were 
prepared 30 h after treatment and dualluciferase assays were performed as described in 
Materials and Methods. Values are luciferasel Renilla luciferase activity normalized to 
the ETOH control for each construct. Values are the mean ± SEM of 4. a = P< 0.05 
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Figure 4S: Effect ofSERMs on luciferase activity from the pGL3-pro-NRF-l-{"1007-
-S07) construct. MeF-7 (A), HEK-293-ERa (B), and HEK-239-ERP (e) cells were 
transfected with pGL3-pro-NRF-l-CI007--807). Twenty-four h later, the cells were 
treated with EtOH, 100 nM 4-0HT, 100 nM RAL, leI 182,780+4-0HT, or leI 
182,780+RAL. weE were prepared 30 h after treatment and dualluciferase assays were 
performed as described in Materials and Methods. Values are luciferasel Renilla 
luciferase activity normalized to the EtOH control for each construct. Values are the 
mean ± SEM of 3 experiments. a = P< 0.05 compared to EtOH; b=P<0.05 compared to 
4-0HT; c=P<O.OS compared to RAL 
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effect was not detected in the pGL-NRF-I-C1100MUT) construct, indicating that the 
ERE is mediating the 4-0HT- and RAL- inducible response (Figure 47). 
ChIP Assays Examining the ER Occupancy of the NRF -1 Promoter in the Presence 
ofSERMs 
Previously, ChIP assays revealed that both ERa and ER~ occupied the NRF-l 
promoter region containing the ERE in vivo in the presence ofE2 (Figure 49). Thus far, the 
mRNA and transfection data have suggested a mixed genomic/nongenomic mode of 4-0HT 
and RAL- induced ER action on the NRF -1 promoter. ChIP assays were performed to look 
at the in vivo binding of ERa and ER~ in the presence of 4-0HT and RAL. ChIP indicated 
an increase in the NRF-l promoter occupancy by both ERa and ER~ after MCF-7 cell 
treatment with either 4-0HT or RAL (Figure 49). 
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Figure 49: ERa and ER~ bind to the putative NRF-l ERE in vivo in the presence of 
4-0HT and RAL. MCF-7 cells were treated with EtOH, 100 nM 4-0HT, or 100 nM 
RAL for 1 h and ChIP was performed as described in Materials and Methods. 
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DISCUSSION 
The goal of the experiments described in this chapter was to examine the effects 
of 4-0HT and RAL on the expression ofNRF-l mRNA and the effects of these ligands 
on the NRF-lluciferase reporter plasmids. The observed increases in NRF-l mRNA in 
MCF -7 cells are lower than those observed by E2 treatment. As previously seen, E2 
treatment yielded a ~4-fold increase in NRF-l (Figure 8) while 4-0HT results in a ~2.5-
fold increase and RAL only stimulated a ~ 1. 7 fold increase (Figures 42 and 43). While 
4-0HT and RAL may increase mRNA expression, they act as weaker inducers ofNRF-l 
transcription in MCF-7 cells in comparison to E2. This effect is not true in H1793 cells. 
H1793 cells displayed a ~2.0-fold increase in NRF-l mRNA in response to E2 whereas 
both 4-0HT and RAL induced a ~2.5 fold increase in NRF-l mRNA. In a cell type 
specific manner, 4-0HT and RAL are increasing NRF-l mRNA more in H1793 cells and 
acting equally efficient as inducers. 
Both genomic and nongenomic mechanisms of 4-0HT and RAL action through 
ER have been documented (177,181). The observed mixed effect of these two modes of 
activation was not expected. The time ofNRF-l mRNA increase, 1 h for 4-0HT and 2 h 
for RAL in MCF-7 cells, suggests a genomic mechanism as does the promoter occupancy 
of the NRF-1 ERE by ERa and ER~ in ChIP experiments. Additionally, data from the 
transient transfection experiments suggests a role for genomic ER binding to the NRF-1 
ERE. Nongenomic effects would be expected in a more rapid time frame of sec to min. 
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In contrast to the effects ofE2, the Wortmannin treatment results clearly point to a 
contribution of the PI3 Kinase pathway to the 4-0HT and RAL induced increase in NRF-
1 mRNA in MCF-7 cells. Wortmannin treatment ofH1793 cells in conjunction with 4-
OHT indicated a contribution of the PI3 Kinase pathway to the 4-0HT stimulated 
increase in NRF-l mRNA, similar to results achieved in MCF-7 cells. However, RAL 
appears to be acting through genomic and both the PI3 Kinase and MAP Kinase 
nongenomic pathways in HI 793 cells. 
The differences seen in activation of the NRF-l gene in response to different ER 
ligands may be due to several cell-type specific differences such as coregulator 
expression (171-173) or AF-1 and AF-2 contributions (182-186). For example, the 
agonist properties of 4-0HT in endometrial tissue are mediated by high levels of SRC-1 
expression allowing the formation of a 4-0HT-ER-SRC-1 complexes on the promoters of 
targets genes (55). In other tissues, such as breast, with lower SRC-l activity the 4-0HT-
ER complex recruits corepressors (55). To date, there is no experimental data in the 
literature comparing coregulator expression patterns in MCF -7 and H 1793 cells. In 
addition to the potential for unique coregulator expression patterns to influence gene 
activation, coregulator recruitment is affected by the conformation of the receptor 
induced by both the ligand and the ERE to which the E2-ER complex is bound (166). 
The contributions of AF-1 and/or AF-2 on the transcriptional control vary in a 
cell- and promoter- type manner (182-186). For example, ERa in MCF-7 cells are 
believed to have signaling mediated more through AF-1 than AF-2 (184,186), while 
HEK-203 cells signal through AF-1 and AF-2 equally (187). Using different promoter 
constructs, 4-0 HT was also demonstrated to act through both AF -1 and AF -2 on some 
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promoters whereas on other promoters, the AF-l and AF-2 function independently. AF-2 
activity was not required in all of the promoters tested (183). In addition to cell- and 
promoter- type dependence of AF-l and AF-2 activity, the contribution of AF-l and AF-
2 toward ERa activity has also been demonstrated to be dependent on the cell 
differentiation stage (186). AF -1 is the predominant AF mediating ER transcriptional 
activity in differentiated cell lines. However, more de-differentiated cells mediate 
signaling through AF-2. For example, AF-2 is functional in cells that have undergone the 
epithelial-mesenchymal transition, but not AF-l (186). 
Overall, I conclude that both 4-0HT and RAL are acting as ER agonists on the 
NRF -1 promoter in both MCF -7 and H 1793 cells. The agonist effect is mediated by 
both genomic and non genomic mechanisms. However, the exact contribution of 
coregulator differences as well as AF-l vs. AF-2 signaling in these cell lines on the NRF-
1 induction of mRNA has yet to be determined. 
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CHAPTER V 
REGULATION OF NUCLEAR RESPIRATORY FACTOR-l EXPRESSION BY 
TAMOXIFEN AND RALOXIFENE IN HUMAN UMBILICAL VEIN ENDOTHELIAL 
CELLS 
INTRODUCTION 
The cardiovascular system is an important target of estrogen action, much like the 
reproductive tissues, brain, liver and bone, through both genomic and nongenomic 
pathways (reviewed in (188)). Expression of both ERa and ER~ have been demonstrated 
using RT-PCR in the coronary arteries of both male and female cynomolgus monkeys 
(189). ERa has been demonstrated in human coronary arteries (190) and ER~ has been 
observed in primary human cardiomyocytes (74). Studies have also linked a decrease in 
mitochondrial respiratory chain activity and a loss of mitochondrial ultrastructure to a 
lack ofER in ERKO and ~ERKO mice (79,81). 
The proposed protective effects of estrogens in the cardiovascular system have 
been challenged by results from the Women's Health Initiative/ Heart and 
Estrogen/Progestin Replacement Study (WHI and HERS). These studies showed no 
significant improvement of CHD in postmenopausal women receiving hormone 
replacement thereby (HRT), which included a mix of conjugated equine estrogens (CEE) 
and medoxyprogesterone acetate (MP A) (191). Instead, HR T increased the incidence of 
CHD (192) and both HRT and ERT increased venous thromboembolism (191,193). In 
postmenopausal women with pre-existing CHD given ERT, the cardioprotective benefits 
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were tempered by the potential increase in breast cancer events due to estrogen exposure 
(194,195). In contrast to the results from the WHI trial, animal models of stroke and 
vascular function have shown an E2-protective effect (196). One of the criticisms of the 
WHIIHERS studies is that the participants were, in general, many years post-menopausal 
at the initiation of HR T treatment (196,197). Studies addressing the time lapse between 
the onset of menopause and initiation of HRT treatment in primates revealed that 
estrogen treatment started immediately following ovariectomy reduced atherosclerotic 
plaque formation in primates fed a moderately atherogenic diet (198). However, if 
administration ofERT was postponed for two years after ovariectomy (the equivalent of 
~six years in humans), there was no reduction in coronary lesions (198). An additional 
critique of the HR T trial has been the use of oral eEE since eEEs contain a minimum of 
10 estrogens in the form of sulfate esters and several equine estrogens not secreted by 
human ovaries (199). In contrast, human ovaries secrete E2 and estrone (Ed (199). Since 
each estrogen has a unique activity profile for ERa and ERP, eEE may not produce the 
same effects as the naturally occurring estrogens (196). More studies taking into account 
the time between the onset of menopause and the beginning of HR T and the form and 
route of administration ofHRT/ERT are needed (200). Lastly, the statistical evaluations 
in the initial studies have been criticized and re-analysis by one scientist did not support 
an increase risk of cardiovascular disease, stroke or venous thromboembolism in patients 
receiving HRT in the WHI trial (197). In conclusion, despite much research, the 
mechanisms through which E2 conveys its protective effect in the vasculature has yet to 
be fully elucidated. 
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SERMs, i.e., 4-0HT and RA.L, have been suggested to have cardioprotective 
effects without the negative side effects ofHRT (137,201,202). With regard to 
cardiovascular disease, TAM has been shown to lower serum lipids and it may protect 
against CHD (52). However the Study of Tamoxifen and Raloxifene (STAR) trial found 
no cardioprotective benefit with 4-0HT or RAL use (203). In contrast, RAL was shown 
to increase proliferation in a cellular model of venous tissue, human umbilical vein 
endothelial cells (HUVEC) (204). Additionally, clinical trials using RAL have 
demonstrated a reduction in plasma LDL levels and fibrinogen levels (205). However, in 
agreement with the STAR trial, the Raloxifene Use for the Heart (RUTH) clinical trial 
revealed that RAL did not significantly affect the risk of CHD, but increased the risk of 
venous thromboembolism and fatal stroke in postmenopausal women (206). However, 
the same critiques that were suggested for the WHI HRT study can also be applied to the 
RUTH study since the average age of the participants was 68 years with 39% being over 
70 and the average time postmenopause was 19 years (207). Ideally, SERMs could 
provide an alternative to HRT/ERT that would be beneficial in preventing CHD and 
stroke (57). 
Recent studies in rats have shown that E2 decreased ROS production and 
increased mitochondrial energy production in intact cerebral blood vessels in vitro and in 
vivo (114). Importantly, these studies identified an increase in NRF-1 protein in the 
cerebral blood vessels examined (93). As discussed in Chapter II, my research identified 
NRF -1 as a primary estrogen responsive gene in MCF -7 breast adenocarcinoma and 
H1793 lung adenocarcinoma cells. The mechanism ofNRF-1 activation in response to 
E2 was genomic, i.e., the result of an ER-mediated increased gene transcription, and 
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resulted in transcription of secondary NRF -1 target genes and an increase in 
mitochondrial activity. The ability ofNRF-1 to increase mitochondrial activity is 
important in tissues such as the heart which consume large amounts of A TP. Therefore, I 
wanted to examine the ability ofE2, 4-0HT, and RAL to potentially change NRF-1 
expression in HUVEC. 
As discussed in Chapter I, DEP have received attention for their potential role as 
endocrine disrupting agents in recent years. Diesel Exhaust Particulate Extracts (DEPE) 
have displayed both anti estrogenic and antiandrogenic properties in cell culture models 
(60-62). It was previously reported that the speed, stopping and starting patterns, and the 
load that a vehicle is carrying can affect the composition of the DEPE generated (208). 
Therefore, it was important to evaluate the antiestrogenic effects of DEPE generated 
under different engine loads and speeds at which a diesel truck was run. In the following 
studies, DEPE were collected from a Japanese diesel truck run on a chassiss dynometer at 
either varying speeds: 20, 50, or 80 kmlh (referred to as S20, S50, and S80) or at a 
constant speed with varying capacity loads 0,50, or 75% (referred to as LO, L50, and 
L 75) by Dr. Ryoichi Kizu and colleagues in Japan (60,208). The six DEPE samples were 
extracted from the filter on which they were collected (60,208) and sent to Dr. Klinge's 
lab. 
In addition to testing the effects of an environmental pollutant, I wanted to 
examine the effects of a phytoestrogen previously studied in our lab (123) on expression 
ofNRF-1 in HUVEC. Resveratrol is a phytoestrogen found in the skin of grapes that has 
been shown to bind and activate ER (122,209). In addition to binding to ER and 
activating transcription in a genomic manner, resveratrol has also been shown to activate 
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the MAP Kinase pathway (59-61). Recently, long term (15 wk) treatment of male mice 
with 200 or 400 mg/kg resveratrol was demonstrated to significantly increase their 
aerobic capacity, 02 consumption (210). Interestingly, resveratrol increased 
mitochondrial number and size and increased the expression of genes mediating oxidative 
phosphorylation and mitochondrial biogenesis including NRF -1 in the gastrocnemius 
muscle (210). Studies using mouse embryonic fibroblasts (MEFs) from Sirtuin 1 
knockout mice (Sirt-I- MEFs) showed that the increase in mitochondrial activity was 
largely explained by a resveratrol-mediated decrease in PGC-la acetylation which 
increased the activity of this coregulator (210). PGC-la is a known coactivator for NRF-
1. An increase in both NRF -1 and PGC-l a activity would further promote the 
transcription of NRF -1 target genes (67). In general, previous studies have suggested a 
chemopreventative and cardioprotective role for resveratrol (124,125,211). If DEPE can 
oppose the positive increase in NRF -1 induced by E2, it would be relevant to examine if 
resveratrol could protect against these negative effects. 
In the following set of experiments, I have shown that E2 and SERMs increase 
NRF -1 transcription which was followed by a subsequent increase in mitochondrial 
Complex IV activity in HUVEC. DEPE inhibited NRF-l expression and prevented an 
increase in NRF-l stimulated by E2, 4-0HT, and RAL. Resveratrol increased NRF-l 
mRNA expression through an apparent genomic ER mechanism and conveyed a small 
amount of protection against the decrease in basal NRF-l mRNA induced by some 
DEPE. 
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MATERIALS AND METHODS 
Cell Culture and Treatments 
HUVEC were obtained from Cambrex Bioscience and maintained in Endothelial 
Cell Basal Medium-2 (EBM-2) supplemented with hydrocortisone, human fibroblast 
growth factor, vascular epidermal growth factor, insulin growth factor-I, ascorbic acid, 
human epidermal growth factor, Gentamicin sulfate, amphotercin-B, heparin, and 2% 
FBS provided in a supplemental kit with the media from Clonetics (hereafter referred to 
as EGM-2 media). Prior to treatment, HUVEC were placed in EBM-2 media containing 
2% CCS-FBS. HUVEC used in these experiments were between passage number 4 and 
8. 
At the time this work was completed, the particulate composition of the DEPE 
was known for LO, L50, and L75. The distribution ofPAHs is given in Table 5. 
RNA Isolation, RT-PCR and Quantitative Real Time RT-PCR (QRT-PCR) 
RNA isolation and subsequent processing to cDNA and analysis by QRT-PCR 
was performed as described in Chapter II. 
Bromodeoxyudridine (BrdU) Proliferation Enzyme Linked Immunosorbant 
Assay (ELISA) 
The Bromodeoxyudridine (BrdU) Cell Proliferation Enzyme Linked 
Immunosorbant Assay (ELISA) Kit (Roche) is a colorimetric immunoassay for the 
quantification of cell proliferation. It is based upon the incorporation of a pyrimidine 
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analogue, BrdU, in place of thymidine into DNA during DNA synthesis. The presence of 
BrdU is detected through binding of an anti-BrdU-POD Fab-fragment which 
subsequently reacts with a substrate generating a detectable colorimetric change. 
For the BrdU assay, HUVEC were seeded at a density of 6000 cells! well in a 96-
well plate. The cells were treated for 48 h with the indicated treatments. To each well, 
10 III of BrdU labeling solution was added, and the cells were incubated for an additional 
2 h allowing time for the incorporation of BrdU into the cellular DNA. The labeling 
solution was removed and the cells were incubated in 200 Ill/well FixDent Solution 
provided with the kit. The cells were incubated at room temperature for 30 min. The 
fixing solution was removed and 100 Ill/well of anti-BrdU-POD solution was added for 
90 min. The cells were rinsed three times with Washing Solution followed by addition of 
IOOIll/well Substrate Solution and incubated at room temperature for 10-20 min. 
Absorbance was measured at 370 nm. Each treatment was performed in quadruplicate 
and the values were averaged. All values were compared with those in the wells treated 
with vehicle (EtOH) control, which was set to 1.0. 
Complex IV Activity Assay 
The MitoProfile Microplate Assay Kit for Human Complex IV Activity was 
purchased from MitoSciences. It was used to determine the activity of Complex IV from 
cell or tissue extracts. In this protocol, Complex IV was immunocaptured and its activity 
determined colorimetrically via the oxidation of reduced cytochrome c. This is measured 
as a decrease in absorbance at 550 nm. 
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HUVEC were seeded at 60% confluency in 6-well plates. The cells were grown 
in EBM-2 media supplemented with 2% CCS-FBS for 24 h. The cells were treated in 
EBM-2 media with 2% CCS-FBS for 6 d. The treatment was reapplied every 2 d. The 
cells were harvested in 100 j.!l of Solution 1 with detergent (included in the kit). Protein 
concentrations were determined using the Bio-Rad DC Protein Assay, and 20 j.!g of 
protein/well was diluted in 200 j.!l Solution 2. The diluted protein was incubated in a 96-
well plated containing bound antibody for Complex IV. After a 3 h incubation, the wells 
were washed and 200 j.!l of Assay Solution added. Absorbance was measured every 5 
min for 75 min. The slope of the reaction leveled off after 75 min. A linear range 
between 20 min and 60 min was examined for all treatments. The rate of Complex IV 
activity was determined by calculating the slope of the line between these two points 
resulting in OD/min change. One experiment was completed and assayed in 
quadruplicate. The EtOH from this experiment was set to 1. 
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Concentration (pmole/mg DEPE» 
Compound LO L50 L75 
pyrene 409 ± 108 806 ± 254 740± 195 
benz [a] anthracene 77.3 ± 38.7 111 ± 82.5 147 ± 63.3 
chrysene 112 ± 58.2 118 ± 90.6 286 ± 140 
benzo[ b ]f1uoranthene 95.7 ± 13.4 68.6 ± 18.2 152 ± 60.9 
benzo[k]f1uoranthene 11.6 ± 3.70 2.70 ± 1.00 17.5 ± 7.00 
benzo [a ]pyrene 19.4 ± 2.20 1.90 ± 0.70 4.30 ± 0.30 
benzo[b]chrysene 0.70 ± 0.20 0.10 ± 0.10 N.D.* 
perylene 7.00 ± 0.40 1.40 ± 0.50 1.20 ± 0.30 
dibenz[ a,h ] anthracene 10.0 ± 4.90 6.60 ± 2.20 6.10 ± 6.50 
benzo[ghi]perylene 13.6 ± 2.00 1.40 ± 2.40 5.20 ± 5.80 
indeno[ 1,2,3 -cdJpyrene 4.00 ± 1.70 N.D.* N.D.* 
dibenzo[a,e ]pyrene 0.30 ± 0.30 0.10 ± 0.30 0.10 ± 0.30 
coronene 0.50 ± 0.40 N.D.* N.D.* 
--------------------------------------------------------
Sum (13 PAHs) 761±217 1118±383 1359 ± 447 
*Not detected, mean ± SD (three separate extract samples). 
Table 5: Concentrations of P AHs Having Four or More Rings in the DEPE Samples 
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RESULTS 
fu, 4-0HT and RAL Increase NRF-l Transcription in HUVEC 
As reported in Chapter II, I established that E2 stimulated NRF -1 gene expression 
through genomic ER action. In addition to E2, 4-0HT and RAL stimulate the expression 
ofNRF-l in HUVEC (Figure 50). HUVEC express both ERa and ERP (212). To 
determine if the increase in NRF-l transcription in response to E2, 4-0HT, and RAL was 
mediated by both ER subtypes or by only one, cells were treated with either PPT, 
selective for ERa (148), or DPN, a selective agonist for ERP (149). Both PPT and DPN 
stimulated the transcription ofNRF-l in HUVEC (Figure 50), indicating that ERa and 
ERP transcriptionally activate NRF-l. Interestingly, the increase in NRF-l mRNA was 
not significantly different in the DPN and PPT treated HUVEC when compared to the E2 
treated cells. This reveals that activation of either subtype can result in complete 
induction ofNRF-l RNA in comparison to E2 treated cells. 
To further evaluate ifER is mediating the E2-, 4-0HT-, and RAL- induced 
increase in NRF-l message levels, HUVEC were pretreated with ICI 182,780 for 6 h 
prior to addition ofE2, 4-0HT, and RAL. This pre-incubation time was selected because 
previous studies had demonstrated a ~80% decrease in ERa protein levels as early as 4 h 
post-treatment with ICI 182,780 (143). ICI 182,780 inhibited the E2-, 4-0HT-, and RAL-
induced increases in NRF -1 mRNA (Figure 51) indicating that ER mediates the induction 
response previously observed. 
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EtOH 4-0HT RAL DPN PPT 
Figure 50: E2, 4-0HT, and RAL activate NRF-l mRNA expression in HUVEC. 
HUVEC were treated with EtOH, 10 nM E2, 100 nM 4-0HT, 100 nM RAL, 10 nM DPN, 
or 10 nM PPT for 4 h. The total mRNA was isolated following treatment and QRT-PCR 
was performed as described in Material and Methods. Values are the average of 3 
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Figure 51: ICI 182,780 blocks the E2, 4-0HT, and RAL stimulated NRF-1 mRNA 
induction in HUVEC HUVEC were treated with 100 nM ICI 182,780 (lCI) for 6 h 
prior to treatment with 10 nM E2, 100 nM 4-0HT and 100 nM RAL for 4 h, as indicated. 
The total mRNA was isolated following treatment and QRT-PCR was performed as 
described in Material and Methods. Values are the average of 3-6 separate experiments ± 
SEM. a = P< 0.05 compared to EtOH; b=P<0.05 compared to E2; c=P<0.05 compared 
to 4-0HT; d=P<0.05 compared to 4-0HT 
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Signaling pathways including the MAP Kinase and PI3 Kinase pathways have 
been shown to be activated by nongenomic E2 activity in HUVEC (213,214). To 
detennine ifE2, 4-0HT, and RAL are acting through these nongenomic pathways, 
HUVEC were pre-treated with the MAP Kinase inhibitor PD98059 or the PI3 Kinase 
inhibitor Wortmannin, and then treated with E2, 4-0HT, and RAL. Neither PD98059 nor 
Wortmannin inhibited the E2-, 4-0HT- or RAL- induced increase in NRF-l mRNA 
(Figure 50). From these results, I conclude that 4-0HT and RAL are acting through 
classical genomic ER to mediate an increase in NRF -1 mRNA, results that parallel the 
effect of E2 in these cells. 
Secondary Gene Expression is Increased in Treated HUVEC 
QRT-PCR was perfonned to look at the effect of 48 h of treatment with E2, 4-
OHT, or RAL in the presence or absence ofICI 182,780 on expression ofTfam in 
HUVEC. This time point was chosen because Tfam, as well as its target genes COl and 
NDI, were all significantly increased in an E2 dependent manner in MCF-7 cells after 48 
h of treatment (Chapter II, Figure 19). As previously discussed, Tfam is a downstream 
target ofNRF-l which is involved in transcription of the mtDNA. E2, 4-0HT, and RAL 
all stimulated an increase in Tfam mRNA (Figure 53). The observed increase is inhibited 
by pretreatment for 6 h with ICI 182,780 followed by cotreatment with ICI 182,780 in the 
E2 and RAL samples. However, treatment with both 4-0HT and ICI 182,780 resulted in 
a decrease that was not significant compared to the control, but was also not significant 
when compared to the 4-0HT treatment alone. 
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In parallel to experiments performed in MCF-7 cells in Chapter II, QRT-PCR was 
used to examine the mRNA expression of two Tfam target genes, COl and NDI, which 
are encoded in the mtDNA. COl and NDI mRNA were both induced by E2, 4-0HT, and 
RAL (Figure 53). Treatment with ICI 182,780 in the presence ofE2, 4-0HT, and RAL 
was able to significantly decrease expression when compared to treatment in the absence 
oflCI 182,780. These results indicate that the observed increase in NRF-l in the 
presence of all three ligands leads to a downstream effect on NRF -1 and Tfam target 
genes. 
Complex IV Activity in Treated HUVEC 
In the mitochondrial respiratory chain, Complex IV serves as the terminal electron 
acceptor, consuming 02 and generating H20. To determine if the observed increase in 
NRF-l mRNA lead to a subsequent increase in mitochondrial activity, Complex IV 
activity was determined using an EIA that colorimetrically measures the oxidation of 
reduced cytochrome c. E2, 4-0HT and RAL increased Complex IV activity and the 
increase in Complex IV activity caused by E2 was reduced by cotreatment with ICI 
182,780 (Figure 54). 
These data agree with the O2 consumption data (Chapter II, Figure 23). The 
results suggest that E2-treatment leads to an increase in NRF -1 gene expression, and also 
stimulates a downstream increase in MRC function. Additionally, 4-0HT and RAL are 
also observed to induce an increase in Complex IV activity. This suggests that 4-0HT 
and RAL are acting in a similar manner to E2, not only in their capacity to induce gene 
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Figure 52: Genomic ER is responsible for the increase in NRF -1 mRN A induced by 
E2, 4-0HT, and RAL. HUVEC were pre-treated with 50 run Wortmannin or 50 ~m 
PD98059 for 1 h followed by 4 h treatment with 10 run E2, 100 nM 4-0HT, or 100 nM 
RAL in the presence of Wortmann in or PD98059. The total mRNA was isolated 
following treatment and QRT-PCR was performed as described in Material and Methods. 
Values are the average of3 separate experiments ± SEM. a = P< 0.05 compared to EtOH 
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Figure 53: Secondary gene mRNA expression is increased in response to treatment 
with E2, 4-0HT, and RAL. HUVEC were treated with 10 nM E2, 100 nM 4-0HT, or 
100 nM RAL. Cells were also pretreated for 6 h with ICI 182,780 followed by addition 
of 10 nM E2, 100 nM 4-0HT, or 100 nM RAL for 48 h. The total mRNA was isolated 
following treatment and QRT-PCR was performed as described in Material and Methods. 
Values are the average of 3 separate experiments ± SEM. a = P< 0.05 compared to EtOH; 
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Figure 54: Effect ofE2, 4-0HT, and RAL on Complex IV activity in HUVEC. 
HUVEC were treated with 10 nM E2, 100 nM 4-0HT, 100 nM RAL, 100 nM ICI 
182,780 or 10 nME2 and 100 nM ICI 182,780 for 6 d. Post-treatment, Complex IV 
activity was measured as described in Materials and Methods. The EtOH control was set 
to 1. The EtOH value was originally 1.13 xl0-4 OD/min. Values are the Average of one 
experiment assayed in quadruplicate ± SEM. a = P< 0.05 compared to EtOH; b = P< 
0.05 compared to E2 
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DEPE Inhibit NRF-l mRNA Expression 
DEPE were reported to act as antagonists ofE2 at the transcriptional level (60). 
They are also prevalent in industrialized cities and thought to pose a significant health 
risk (59,60). A recent epidemiological study suggested that living in a high traffic area 
may be an important risk factor for CHD (121). Since NRF-l is important to 
cardiovascular health through maintenance of mitochondrial function (79-S1,93), I 
wanted to determine the effect ofDEPE on the transcription ofNRF-l. HUVEC were 
treated with the highest concentration (10 mg/mL) of each DEPE and NRF-l mRNA 
expression was quantified by real time PCR. L50, L75, and SSO significantly inhibited 
basal NRF-l expression by 25-40% (Figure 55). 
A concentration-response titration for L50, L 75, S50, and SSO was performed in 
conjunction with a single concentration ofE2 (10 nM) to determine the optimal inhibitory 
concentration of these DEPE. At only the maximum concentration tested (10 mg/ml), 
L50 alone significantly inhibited basal NRF-l mRNA expression. In contrast, L75 
inhibited basal levels ofNRF-l transcription at all three concentrations tested (Figure 
56). In conjunction with E2, both L50 and L75 inhibited the E2-induced increase in NRF-
1 at all three concentrations. However, the combination ofL50 plus E2 still resulted in an 
increase in NRF-l mRNA compared to the effect of the L50 treatment alone, whereas 
L75 inhibited NRF-l expression to levels equivalent to that seen with L75 alone, i.e., 
significantly below basal (per the a and b designations) (Figure 56). S50 significantly 
blocked basal expression ofNRF-l at only the middle concentration tested (1mg/ml), and 
SSO was able to suppress basal NRF-l mRNA transcription at only the 10 mg/ml 
concentration (Figure 57). However, S50 exhibited a concentration-dependent inhibition 
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of the E2 induced stimulation ofNRF-l at the 1 mg/ml and 10 mg/ml concentrations 
(Figure 57). All concentrations ofS80 inhibited the E2-induced increase in NRF-lmRNA 
(Figure 57). 
Next, I determined if the DEPE exhibiting the concentration that exhibited the 
greatest inhibition on NRF-l transcription, L75 and S80, had an impact on the observed 
E2, 4-0HT-, and RAL- induced increase in NRF-l mRNA expression in HUVEC. L75 
and S80 inhibited the E2, 4-0HT-, and RAL- mediated increase in NRF-l mRNA (Figure 
58). I conclude that, in regards to the NRF-lmRNA expression, L75 and S80 appear to 
act as antagonist on the E2, 4-0HT-, and RAL- induced stimulation ofNRF-l. 
DEPE Do Not Stimulate Cell Proliferation in HUVEC as Assessed in BrdU Assays 
BrdU assays were conducted to determine ifDEPE were stimulating cell 
proliferation. E2 treatment of HUVEC displayed an increase in DNA proliferation 
(Figure 59). However, 4-0HT, RAL, L50, L 75, S50, and S80 treatment did not result in 
any change in cell proliferation. This indicated that the changes in NRF-l levels do not 
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Figure 55: L50, L 75, and S80 inhibit basal transcription of NRF -1 in HUVEC. 
HUVEC were treated with 10 mg/mL of each DEPE indicated for 4 h. The total mRNA 
was isolated following treatment and QRT-PCR was performed as described in Material 
and Methods. Values are the average of 3 separate experiments ± SEM. a = P< 0.05 
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Figure 56: L50 and L75 inhibit the E2-induced increase in NRF-l at all 
concentrations tested in HUVEC. HUVEC were treated with 0.1, 1.0, or 10 mglmL of 
L50 or L75 in the presence or absence of 10 nM E2 for 4 h. The total mRNA was 
isolated following treatment and QRT-PCR was performed as described in Material and 
Methods. Values are the average of 3 separate experiments ± SEM. a = P< 0.05 
compared to EtOH; b=P<0.05 compared to E2; c = P< 0.05 compared to the 
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Figure 57: S80 inhibits the E2-induced increase in NRF-l at all concentrations tested 
in HUVEC. HUVEC were treated with 0.1, 1.0, or 10 mg/mL of SSO or S80 in the 
presence or absence of 10 nM E2 for 4 h. The total mRNA was isolated following 
treatment and QRT-PCR was performed as described in Material and Methods. Values 
are the average of 3 separate experiments ± SEM. a = P< O.OS compared to EtOH. 
b=P<O.OS compared to E2; c = P< O.OS compared to the corresponding concentration 










·0 1.0 d ~ .... 
0.5 
0 
EtOH E2 4-0HT RAL L75 S80 L75 S80 L75 S80 L75 S80 
+ E2 +E2 +4-0HT +4-0HT +RAL +RAL 
Figure 58: L 75 and S80 inhibit the E2-, 4-0HT -, and RAL-induced increase in 
NRF-l mRNA in HUVEC. HUVEC were treated with 10 nM E2, 100 nM 4-0HT, and 
100 nM RAL alone or in combination with 10 mg/mL of L 75 or S80 in the indicated 
combinations for 4 b.. The total mRNA was isolated following treatment and QRT-PCR 
was performed as d¢scribed in Material and Methods. Values are the average of 3 
separate experiments ± SEM. a = P< 0.05 compared to EtOH; b=P<0.05 compared to E2 
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Figure 59: DEPE do not induce cell death in HUVEC. HUVEC were treated with 
EtOH, 10 nM E2, 100 nM4-0HT, 100 nM RAL, 10 mg/m1 LSO, 10 mg/m1 L75, 10 mg/m1 
S50, or 10 mg/ml S80 for 48 h prior to performing the BrdU assay. Cells were assayed to 
look for a proliferati~e response as described in Materials and Methods. Values are the 
average of 3 separate experiments ± SEM. a = P< 0.05 compared to EtOH 
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Resveratrol Induces an Increase in NRF -1 Through Activation of Genomic ER 
Resveratrol, a phytoestrogen found in grape skins (209), has been shown to bind 
to and activate ER with low affinity (122) and have cardioprotective capabilities 
(124,125). Resveratrol increased NRF-l mRNA expression in a concentration-dependent 
manner (Figure 60A). To determine ifnongenomic ER signaling or genomic ER 
activation was responsible for mediating this response, Wortmannin, PD98059, Pertussis 
Toxin, and ICI 182,780 were used in combination with resveratrol to treat HUVEC. 
Only ICI 182,780 inhibited the resveratrol-induced increase in NRF-1 mRNA, indicating 
that genomic ER is responsible for the increase in NRF-1 (Figure 60B). 
To determine ifresveratrol could convey protection against the observed decrease 
in NRF-l transcription by DEPE, HUVEC were pretreated with 100 nM resveratrol for 
24 h prior to the addition of 10 mg/ml of 4 different DEPE for 4 h. As anticipated from 
data shown in Figures 55 and 56, L50, L 75, and S80 all inhibited basal expression of 
NRF-1 mRNA (Figure 61). The resveratrol pre-treatment was able to prevent the 
reduction in basal level expression ofNRF-1 by L50, L75, and S80. In the case ofL75 
and S80, resveratrol pre-treatment lead to an increase in NRF-1 when compared to the 
respective DEPE treatment alone. However, the expression ofNRF-1 seen with the 
combination of resveratrol and L50, L 75, and S80 was significantly lower compared to 
the sample treated with resveratrol alone. S50 treatment did not inhibit basal NRF-1 
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Figure 60: Resveratrol increases NRF -1 mRNA expression in a concentration-
dependent manner through genomic ER activity in HUVEC. (A) HUVEC were 
treated with increasing concentrations ofresveratrol (Res). (B) HUVEC were pretreated 
with 100 nM ICI 182,780 for 6 h or 50 nM Wort or 50 flM PD or 50 nM Pertussis Toxin 
(Ptx) for 1 hr followed by the addition of 10 nM resveratrol for 4 h. The total mRNA was 
isolated following treatment and QRT-PCR was performed as described in Material and 
Methods. Values are the average of 3 separate experiments ± SEM. a = P< 0.05 





















Figure 61: Resveratrol prevents basal suppression of NRF -1 transcription by L 75 
and S80 in HUVEC. HUVEC were incubated with 100 nM Res for 24 h prior to the 
addition of 10mg/ml ofthe indicated DEPE for 4 h. The total mRNA was isolated 
following treatment and QRT-PCR was performed as described in Material and Methods. 
Values are the average of 3 separate experiments ± SEM. a = P< O.OS compared to EtOH; 




Estrogens and SERMs have been proposed to have cardioprotective affects; 
however the mechanisms by which these effects are conveyed remain to be elucidated. I 
propose that one of these protective mechanisms may be an increase in NRF -1 leading to 
a subsequent increase in mitochondrial number and activity. Here I report that E2 and the 
SERMs 4-0HT and RAL increased NRF-l gene transcription in HUVEC. Additionally, 
I observed that DEPE inhibited basal NRF-l expression and DEPE also inhibited the 
ability ofE2, 4-0HT, and RAL to induce NRF-l expression. The phytoestrogen 
resveratrol can act in a protective manner to prevent some of the decreases seen using the 
DEPE extracts. 
Although nongenomic signaling by E2 and SERMS in HUVEC is well established 
(214), my studies showed that E2 and SERMs increase NRF -1 gene transcription 
independent of the MAP Kinase and PI3 Kinase pathways. Instead, this series of 
experiments revealed that NRF -1 induction was stimulated through genomic ER in 
response to both E2 and the SERMs 4-0HT and RAL. This contrasts the results from 
MCF-7 and H1793 cells in Chapter IV. While the E2 mediated increase in NRF-l mRNA 
was activated through genomic ER in all three cell lines, only HUVEC demonstrated a 
genomic mode ofNRF-l mRNA induction through 4-0HT and RAL. Previous data 
(Figures 44 and 45) indicated involvement of the PI3 Kinase pathway in induction of 
NRF-l transcription in response to either 4-0HT or RAL in MCF-7 cells. In MCF-7 
cells, the data suggested a role for genomic ER signaling and nongenomic signaling in 4-
OHT and RAL treated samples. Both nongenomic and genomic signaling was also 
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observed in 4-0HT and RAL treated H1793 cells. It is not known why genomic 
signaling appears to be the predominant mode ofNRF-1 mRNA activation in HUVEC. 
However, this observation does indicate the complexity in signaling pathways between 
diverse cell types in regards to NRF-1 activation. The observation that 4-0HT and RAL 
can act as inducers of a protein important for mitochondrial maintenance, and therefore 
important in tissues such as the heart that require large amounts of energy, is unique. 
While the series of molecular events that lead to cardiovascular disease and dysfunction 
are complex and multifaceted, a down- or up- regulation in an important integrator of 
nucleo-mitochondrial interactions such as NRF-1 is notable. The upregulation ofNRF-1 
by E2, 4-0HT, and RAL could be one mechanism by which these compounds convey 
their cardioprotective effects, although the extent of these effects is still controversial. 
It was interesting to note that the HUVEC increased transcription ofNRF-1 
mRNA in response to both PPT and DPN in an equivalent manner (Figure 49). In 
experiments done in MCF-7 cells, the activation ofNRF-1 correlated with the expression 
levels of either subtype (Figure 12). HUVEC express both ERa and ER~ (215). Both 
PPT and DPN induced an increase in NRF-1 mRNA that was not statistically different 
from the E2-stimulated response. This indicates that either subtype can fully induce 
NRF -1 mRNA expression in this cell line. The importance of ERa vs. ER~ in the 
vasculature has been debated in the literature. Studies in ERKO and Ovx rodents have 
suggested an important role for ERa in maintaining mitochondrial structure and function 
in an ischemic reperfusion model (79). It has also been reported that ~ERKO mice show 
a decrease in vascular function compared to wild type animals implying a role for ER~ in 
the vasculature (84). In a recent report examining a model of trauma-hemorrhage, PPT 
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and DPN were used to demonstrate that the protective effects E2 were mediated through 
ER~ in the cardiovasculature (216). 
DEPE are known to have both anti androgenic and antiestrogenic effects in cell 
culture models (60-62). It is also well known that high levels of particulate matter (PM) 
in air pollution are associated with an increased risk in cardiovascular disease. Acute 
exposure to air pollution has been reported to increase cardiac disease mortality (217), 
and inhalation of high urban levels of concentrated ambient fine PM and ozone for 2 h 
caused conduit arterial vasoconstriction in healthy adults (218). However, the 
mechanisms mediating the effects of airborne PM pollutants are complex. Results from 
the present study allow me to propose that one component of the observed increase in 
cardiovasculature disease mediated by PM may be a decrease in NRF -1 expression and a 
loss of the beneficial effects of E2 when these particles are present. The subtle decrease 
in mitochondrial activity that could result from this scenario may contribute to the 
observed increase in cardiovascular risk in urban areas (59,60). 
The resveratrol data presented in this Chapter suggests that resveratrol mediates a 
genomic activation ofER in HUVEC leading to an increase in NRF-l mRNA. This 
contrasts recent data from mouse studies suggesting a role for resveratrol in increasing 
mitochondrial biogenesis and activity by upregulating PGC-la through SIRTI (210). 
SIRTI is a protein deacetlyase known to be activated by resveratrol (210,219). In recent 
studies, resveratrol-induced SIRTI activity was shown to activate PGC-la by 
deacetylation without change ofPGC-la expression (210,219) leading to an increase in 
genes related to mitochondrial biogenesis and oxidative phosphorylation, including NRF-
1 and the NRF -1 target gene Tfam (210). An increase in liver mitochondrial number was 
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also observed in male mice fed high doses (400 mg/kg/day) of resveratrol for 15 wks. 
(219). In micro array data, mice feed a diet high in resveratrol displayed double the NRF-
1 mRNA levels compared to the mice feed a diet free of resveratrol (210). These 
microarrays were performed using muscle tissue. It is interesting to note that the authors 
did not detect and increase in mitochondrial biogenesis stimulated by resveratrol in the 
heart under the conditions tested (210). As previously mentioned, the mode of gene 
activation is likely not only to be multifaceted but differ in between tissue types. 
Therefore, while the aforementioned studies provide important insight into the action of 
resveratrol in mitochondrial function in these mice, I do not think they dismiss a potential 
role for an ER mediated induction ofNRF-l in other cell types, i.e., HUVEC. 
The results presented in this Chapter have demonstrated a role for genomic ER in 
regulating NRF-l expression in response to E2, 4-0HT, RAL, and resveratrol in HUVEC. 
I have also demonstrated a negative impact ofDEPE on NRF-l expression and a loss of 
the beneficial effects ofE2, 4-0HT, and RAL in the presence of the DEPE. Resveratrol 
was able to protect against the decrease in basal level NRF -1 expression resulting from 
DEPE treatment. Together these results lay the foundation for future experiments further 




There is a clear effect of estrogens on the function and maintenance of 
mitochondria as demonstrated by numerous studies (79,80,87,106,108-112,114,117-120). 
How this beneficial effect is mediated is not well defined and may be multifaceted. For 
example, E2 can act directly as an antioxidant (220,221) and in this capacity does not 
require ER. However, a role for ER in mediating many of the positive effects ofE2, such 
as an increase in Complex IV activity and increases in mitochondrial 02 consumption and 
number has also been discussed at length in the literature (79,81-83,110,114). 
Conversely, the mechanism by which ER is mediating these beneficial effects has not 
been well defined. In this body of work, I have attempted to elucidate one of the 
potential mechanism by which ER can induce the positive increases in mitochondrial 
function and maintenance previously described (79,81-83,110,114). I have examined the 
ability of E2 and other ER ligands to increase the expression of an important integrator of 
nucleo-mitochondrial interactions, NRF-l, that serves to coordinate a global increase in 
mitochondrial function. 
On a physiological level, one might question the relevance of a small E2-induced 
increase in the expression ofNRF-l and mitochondrial activity in general. Indeed, why 
would it be evolutionarily beneficial for NRF -1 expression to be enhanced by E2? There 
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are, of course, several lines of thought on this matter. During the course of a lifetime, 
women are exposed to fluctuating levels of E2 (22). On a cyclical basis, E2 is secreted by 
the ovary during the proliferative phase of the menstrual cycle leading to an increase in 
cell proliferation in the stroma and endometrial glands (222,223). The increase in E2 
production lasts 10-14 d and is accompanied by a subsequent rise in progesterone levels 
after ovulation (222,223). During pregnancy there is an increase in circulating E2 
resulting in a variety of phenotypic changes, i.e., increase in breast ductal tissue in 
preparation for lactation and an increase in uterine volume. Both increases require an 
increase in available energy; therefore, an increase in mitochondrial number and activity 
would be beneficial to support these physiological changes. In addition to the changes in 
breast and uterus during pregnancy, there is also a greater demand on the cardiovascular 
system due to an increase in blood volume (reviewed in (224,225)). Again, it would be 
advantageous to upregulate mitochondria in the cardiovascular system in response to E2 
in order to help fill the increased demand in energy. In line with this reasoning, a 
mitochondrial disorder normally asymptomatic during regular activity resulted in a high 
rate of preeclampsia in a family carrying the mitochondrial disorder (226). This report 
suggested that several characteristic features of preeclampsia, including vasoconstriction 
and disturbed ion transport may, in fact, result from previously undiagnosed 
mitochondrial dysfunction (226). While, NRF -1 was shown to be increased in the 
cerebral blood vessels ofOvx rats chronically treated with E2 (114). However, no one 
has examined how E2 affects the expression of NRF -1 in human cardiovascular samples. 
Ischemia-reperfusion and trauma-hemorrhage models have demonstrated the 
importance of both E2 and ER in protecting against tissue damage (79-81,216). While 
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mouse knockout studies demonstrated that ER(a or ~- or both) can mediate these 
protective effects (79-81,216), exactly how ER was able to convey these effects was not 
identified. Several theories have emerged in the literature. Some researchers have 
proposed that the protective effects of E2 are mediated by ER localized to the 
mitochondria (74,76,138,152), and they propose that E2 acts directly on mtEREs to 
increase the expression of mitochondrial-encoded genes to mediate this effect (76,138). 
However, this theory seems unlikely since upregulating the expression of only the few 
subunits encoded by the mitochondrial genome would not result in functioning 
complexes. Only one nuclear-encoded mitochondrial gene, cytochrome c oxidase subunit 
VII (COVII) is known to have a functional ERE in the promoter (227). It has been 
suggested that more nuclear-encoded mitochondrial genes could contain EREs (110), 
although this has not been demonstrated to date. Even if the existence of a few more 
mitochondrial genes containing ERE where found, it would certainly not account for a 
global upregulation of mitochondrial function. Of course, ER regulates gene 
transcription via tethering mechanisms involving other transcription factors such as AP-1 
and Sp 1 bound to their response elements and responsive elements in addition to EREs 
may be involved in regulation of gene transcription involved in OXPHOS. On the other 
hand, others have proposed that mitochondrial-localized ER conveys its mitochondrial 
protective effects by increasing the activity of manganese superoxide dismutase 
(MnSOD) in the mitochondria and protecting against an increase in ROS (228). 
However, this mechanism would not explain previously demonstrated increases in 
mitochondrial cristae area, Complex IV activity and protein levels, and O2 consumption. 
In this Dissertation, I have presented scientific evidence supporting an alternative 
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hypothesis for the previously observed beneficial effects ofE2 on mitochondrial function. 
I propose that ER regulation ofNRF-lcould explain the increases in mitochondrial 
function and maintenance of mitochondrial ultrastructure previously observed in response 
to E2. While my research does not rule out a role for mitochondrial-localized ER, it does 
present a new theory of ERs mechanism of mitochondrial protection. 
Interestingly, although I did not originally anticipate that 4-0HT and RAL would 
be positive regulators ofNRF-l via ER activation because these SERMs have ER 
antagonist activity in MCF-7 and H1793 cells, here I report the novel observation that 4-
OHT and RAL increase NRF-1 transcription. The activation ofNRF-1 in response to E2, 
4-0HT, and RAL in three different cell types further emphasizes the complexity of 
predicting gene responses and applying models of activation across cell and tissue types. 
Both SERMs have been proposed to have cardioprotective effects (52,57,137,201,202), 
although the extent of these effects is currently unclear (204,207,221). However, the 
ability of 4-0HT and RAL to upregulate NRF-1 mRNA levels, secondary gene 
expression, and Complex IV activity in HUVEC suggests a potential to increase 
mitochondrial activity leading to a possible cardioprotective effect. In line with this 
hypothesis, the ability of DEPE to antagonize the stimulatory effects of E2, 4-0HT and 
RAL on NRF -1 expression suggests a mechanism by which diesel PM pollution may 
increase the risk for cardiovascular disease. Inclusively, the effects of 4-0HT, RAL, and 
DEPE on NRF -1 expression provide an interesting area of study into the contribution of 
these compounds to cardiovascular disease. More importantly, it would be interesting to 
know in future experiments if the ER agonist effects of 4-0HT and RAL or the 
antiestrogenic activity of DEPE will be seen in other tissues. While there is little data on 
157 
the neuroprotective role of SERMs, there is evidence in the literature to suggest that they 
may mediate some beneficial effects (reviewed in (229)). 
In addition to the observations made in the DEPE experiments, it is important to 
note a potential cardioprotective role for resveratrol in protecting against the DEPE 
reduction in NRF-l basal levels. While resveratrol is regarded as a cardioprotective 
agent (124,125,211), the mechanisms by which these effects are conveyed are not fully 
understood. The nongenomic effects of resveratrol in cardioprotection have been 
examined in some detail previously (215,230). However, in this Dissertation, I have 
suggested a new mechanism through which resveratrol may convey cardioprotection by 
stimulating genomic transcription ofNRF-l. Future studies of the downstream effects of 
this stimulation, as well as the coordinated effort of nongenomic and genomic 
mechanisms, will be needed to completely understand the cardioprotective effects of 
resveratrol. 
Understanding the mechanisms involved in mitochondrial dysfunction is 
important in a variety of pathological conditions such as, heart disease, 
neurodegenerative disorders, and cancer. It has been suggested that administration ofE2 
or a SERM may provide beneficial effects in these various conditions 
(110,137,188,196,201,202,229). However, until the mechanisms regulating the effects of 
E2 and their mediation by ER are determined, developing treatment regimens using E2 or 
SERMs will be difficult to approach. The work contained with in this Dissertation is 
unique because it addresses a potentially important pathway for ER mediation of the 
advantageous E2 effect seen on mitochondrial function in multiple cell types. 
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